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CHAPTER I 
 
BACKGROUND AND SIGNIFICANCE 
 
Pathological retinal angiogenesis (retinal neovascularization) is the leading cause of 
severe vision loss and irreversible blindness in developed countries, affecting people of 
all ages (1). It is the characteristic pathological event of diverse retinal diseases, such as 
diabetic retinopathy, retinopathy of prematurity (ROP), retinal vein occlusion, and sickle 
cell retinopathy. Gaining the ability to control retinal angiogenesis does not only benefit 
clinical therapy, but also has an enormous scientific appeal. Despite tissue specific 
aspects, retinal neovascularization shares many common features with other pathological 
angiogenic conditions, such as in tumorigenesis, rheumatoid arthritis and atherosclerosis 
(2). The eye, per se, constitutes an ideal model to study the molecular mechanisms of 
both physiological and pathological blood vessel growth. There exist various reliable 
animal models of ocular angiogenesis. Retinal vasculature can be accessed easily in vivo 
for manipulation and visualization. More importantly, genes can be selectively expressed 
in the retina (3). As a result, interest in ocular neovascularization is growing rapidly.  
In 1950s, professor I. C. Michaelson pioneered the research of the development and 
pathophysiology of the retinal vasculature, and laid the groundwork for generations of 
ophthalmic scientists. The retina is nourished by two independent circulatory systems: 
retinal vasculature and choroidal vasculature. The inner (vitreous) half of the retina 
receives blood supply directly from the retinal vasculature. Arterioles and venules 
permeate the inner retina, forming a superficial capillary network just beneath the surface 
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of the retina and a deep network at the level of the inner nuclear layer. The outer (scleral) 
retina is completely avascular and receives oxygen and nutrients from the underlying 
choroidal circulation by diffusion (4). In infants born prematurely, retinal vascular 
development may be arrested by oxygen supplementation. In diseases, such as diabetes 
and sickle cell disease, normal retinal circulation may be interrupted by vessel atrophy or 
occlusion. These pathophysiological courses are often followed by proliferative retinal 
blood vessel growth. The new blood vessels can be either intraretinal or preretinal (i.e. 
growing into the vitreous cavity). The preretinal vessels are abnormal. They lack lumina 
and are prone to leak, which can result in vitreous hemorrhage, scarring, and tractional 
retinal detachment, leading to severe and permanent vision loss (3). The correlation of 
retinal ischemia and hypoxia of the nonperfused retinal tissue and the subsequent retinal 
neovascularization points to the presence of possible hypoxia-induced retinal angiogenic 
factor(s) (5,6). 
During the last four-decades of research, vascular endothelial growth factor (VEGF, 
also referred to as VEGF-A) was defined as a primary candidate for driving ocular 
neovascularization, despite other factors which may also contribute (2). VEGF expression 
can be induced by hypoxia (7) in retinal cells (8,9). Its expression is both temporally and 
spatially correlated with ocular angiogenesis in animal models (10,11). Increased VEGF 
levels were found in ocular fluids from patients with various forms of retinal angiogenic 
conditions (12). Overexpression of VEGF in the mouse retina was shown to be sufficient 
to induce neovascularization (13). 
During ischemia and hypoxia, the retina uses a common response pathway which is 
employed by most, if not all, tissues to activate specific genes to deal with the crisis and 
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restore oxygen homeostasis, for example, by restructuring blood supply. Deregulation of 
this pathway can lead to retinal neovascularization (14). Reduced oxygen tension is 
sensed possibly by a cytosolic membrane bound heme protein (15), which activates 
transcription factor hypoxia inducible factor-1 (HIF-1) (16) via a signaling cascade 
involving protein phosphorylation (17,18). HIF-1 is an α/β heterodimer, which serves as a 
central regulator of hypoxic gene expression. By binding to the targeted genes, it 
stimulates the transcription of multiple genes that are upregulated under hypoxia, 
including VEGF (14).  
VEGF (or VEGF-A) belongs to a gene family which also includes VEGF-B, VEGF-
C, VEGF-D, and placental growth factor (PLGF). As the prototype member of this gene 
family, VEGF is a key regulator of blood vessel growth. VEGF-C and VEGF-D regulate 
lymphatic angiogenesis (19). VEGF is a heparin-binding homodimeric glycoprotein of 45 
kDa (20). It exists in at least six isoforms (121-, 145-, 165-, 183-, 189-, and 206-amino 
acid isoforms) in human (19,21,22), and three isoforms (120-, 164-, 188-amino acid 
isoforms) in the rodent (23). These isoforms are generated via alternative splicing from a 
single VEGF gene. While VEGF121/120 is freely diffusible, VEGF189/188 and VEGF206 are 
primarily associated with the cell surface and the extracellular matrix (ECM). 
VEGF165/164 has both properties, as a fraction is diffusible while some is sequestered (24). 
The ECM-bound VEGF isoforms may be released to generate bioactive fragments (25). 
Different VEGF isoforms possess distinct functions in vascular development (26-28). 
VEGF165/164 may play an important role in pathogenesis of retinal neovascularization 
(29,30).  
In endothelial cells, the biological effects of VEGF are mediated through its high  
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affinity receptors, VEGFR-1 (flt-1) and VEGFR-2 (KDR in human/flk-1 in the rodent) 
(31-34). VEGF receptors belong to the superfamily of tyrosine kinase receptors. Both 
receptors have seven immunoglobulin-like domains in the extracellular region, a single 
transmembrane domain, and a split intracellular tyrosine kinase domain (35-37). VEGFR-
2 is the major mediator of biologically-relevant VEGF signaling in endothelial cells 
(19,38-40). Stimulation of endothelial cells with VEGF leads to receptor dimerization 
and autophosphorylation. Activated VEGF receptors subsequently initiate intracellular 
signal transduction cascades which consist of a battery of signal molecules, such as 
phospholipase C-γ (PLC-γ), phosphoinositide 3΄-kinase (PI 3-kinase), Ras GTPase-
activating protein (GAP), and mitogen-activated protein kinase (MAPK), and focal 
adhesion kinase (FAK), among others. Initially identified as a vasopermeability factor, 
VEGF exerts profound impact on multiple facets of endothelial cell function, such as 
proliferation, chemotaxis, survival and differentiation (Figure 1.1) (41,42). 
As membrane-attached nonreceptor protein tyrosine kinases, broadly expressed Src 
family kinases (SFKs) link a variety of extracellular cues to intracellular signal pathways 
(43). Family members Src, Fyn and Yes are often coexpressed, such as, in vascular 
endothelial cells (43-45). Recent studies revealed that SFKs were involved in both 
hypoxia-induced VEGF expression in cancer cells (18) and VEGF signaling in 
endothelial cells (46-48). However, their roles in pathological angiogenesis, such as 
VEGF-mediated retinal neovascularization, are unknown.  
Src was first identified as the transforming protein (v-Src) of the oncogenic 
retrovirus, Rous sarcoma virus (RSV) (49). Its highly conserved cellular homologs (43) 
are ubiquitously expressed. So far, nine SFK members have been identified. Src, Fyn and 
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Figure 1.1. Schematic illustration of VEGFR-2 intracellular signaling. Downstream 
signal transduction molecules carry a propagating signal regulating several different 
endothelial cellular functions such as survival, permeability, migration and proliferation. 
Abbreviations: cPLA2, cytosolic phospholipase A2; eNOS, endothelial nitric oxide 
synthase; Erk, extracellular regulated kinase; HSP27, heatshock protein 27; MAPKAPK 
2/3, MAPK-activating protein kinase-2 and 3; NO, nitric oxide; PGI2, prostacyclin; PIP3, 
phosphatidylinositol (3,4,5)-trisphosphate; Sck, Shc-like protein; SPK, sphingosine 
kinase. (Cross MJ et al. Trends Biochem Sci 2003, 28:488-494) 
Yes are broadly expressed, while, others (e.g. Hck, Blk, Lck) have more restricted 
expression patterns and are present only in certain tissues. SFKs are 52 to 62 kDa 
proteins consisting of six distinct functional domains: a) a lipid modified Src homology 
(SH) 4 domain, which is involved in targeting SFKs to cellular membranes; b) a unique 
domain, which is distinct for each member; c) a SH3 protein-binding domain; d) a SH2 
protein-binding domain; e) a catalytic domain, which possesses tyrosine-specific protein 
kinase activity; and finally f) a short negative regulatory carboxyl terminal tail. The 
kinases are maintained inactive by intramolecular interactions of SH3 and SH2 domains 
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with amino acids located within and adjacent to the catalytic domain. The association of 
the SH2 domain with phospho-Tyr527 in the negative regulatory tail is particularly 
important for suppressing kinase activity in some SFKs. These intramolecular 
interactions can be regulated by membrane-linked receptors and docking proteins. Once 
this “closed” configuration is "opened", the intrinsic SFK tyrosine kinase activity is 
activated by phosphorylation of a key tyrosine residue (Tyr416) in the catalytic domain 
(43). The phosphorylation state of Tyr416 is directly correlated with SFK catalytic 
activity (50). SFKs are involved in signal transduction pathways of a diversity of 
receptors, such as immune recognition receptors, integrin and other adhesion receptors, 
and receptor protein tyrosine kinases (RPTKs), and facilitate cross talk between these 
receptors. SFKs can also be activated in response to stress, such as during ultraviolet C 
irradiation, heat, or hypoxia. These kinases regulate a variety of cellular events, including 
cell growth, survival and differentiation, cytoskeletal arrangement, migration, gene 
transcription and other biological activities (43).  
It is known that coexpressed SFKs (e.g. Src, Fyn and Yes) often play redundant roles; 
deficiency in one SFK member can be compensated by others (43,51). However, 
knockout mice deficient in one or more SFKs revealed that Src, Fyn or Yes was likely to 
possess unique functions as well (51). Particularly, Eliceiri and colleagues demonstrated 
that Src- or Yes-, but not Fyn-, deficient mice displayed impaired VEGF-induced 
vascular permeability (46). Systemic administration of PP1 (a broad spectrum SFK 
inhibitor) to mice showed the potential to prevent secondary tissue damage from 
increased VEGF-mediated vascular permeability [e.g. in the pathophysiolology of stroke 
(52)]. In the eye, VEGF-mediated vascular permeability is notoriously responsible for 
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extravasation in both proliferative retinopathy, and many nonproliferative pathological 
conditions, such as aphakic/pseudophakic cystoid macular edema, retinoblastoma, and 
ocular inflammatory disease (3,13,53,54). Thus, selective inhibition of Src or Yes in the 
eye may greatly reduce many types of ocular edema.  
In summary, pathological retinal angiogensis shares many features with physiological 
retinal vascularization. Blocking common pro-angiogenic events would potentially 
endanger existing vasculature and compensatory intraretinal revascularization. Thus, 
ophthalmic scientists are eagerly searching for new therapeutic strategies that can 
selectively target pathological neovascularization. SFKs are involved in both the 
hypoxia-induced VEGF expression pathway and the VEGF downstream signaling 
pathway. Family members likely play differential roles in these cellular events. Thus, 
those SFK members which actively contribute to the pathogenesis of a disease may be 
selectively targeted for inhibition, while avoiding members that are essential for 
maintaining physiological functions. The goal of this dissertation is to dissect and 
characterize molecular mechanisms and biological functions that are regulated by SFKs 
and related to retinal neovascularization. Our intention is to contribute to the scientific 
and clinical knowledge of VEGF- and SFK-mediated biological events.  
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2.1. Abstract 
Retinal capillary quiescence is regulated by a delicate balance between proangiogenic 
and anti-angiogenic factors. Pathological angiogenesis is the result of a shift in this 
balance towards proangiogenic influences. Retinal neovascularization is produced in a rat 
model of oxygen-induced retinopathy (OIR) by exposing newborn rat pups to alternating 
periods of hyperoxia and hypoxia. Based upon previous work, two similar exposure 
paradigms were investigated and compared, exposure of rat pups to alternating periods of 
45 and 12.5% oxygen, and to alternating periods of 40 and 15% oxygen. The resulting 
retinal pathology was assessed by measurement of retinal clock hours with pathological 
blood vessel growth and the percentage of the retina that is avascular. The 45 and 12.5% 
exposure produced significantly greater incidence and severity of pathology than the 40 
and 15% protocol. To explain the difference in pathology between these two very similar 
exposure protocols, retinal levels of proangiogenic VEGF and VEGFR-2 and anti-
angiogenic pigment epithelium-derived factor (PEDF) were measured by ELISA and 
western blot analysis at 0, 2, and 6 days post-exposure. In whole retinal lysates, there 
were no significant differences in VEGFR-2 and PEDF levels. However, VEGF levels 
were approximately 48 and 78% higher on post-oxygen exposure day 0 and 2, 
respectively, in the group treated with alternating periods of 45 and 12.5% oxygen 
compared to the group treated with alternating periods of 40 and 15% oxygen. There was 
no significant difference in VEGF levels between these two groups on day 6 post-
exposure. Therefore, the difference in pathology observed between these two 
experimental paradigms is associated with differences in whole retinal VEGF levels, but 
not changes in whole retinal VEGFR-2 or PEDF levels. The results of this study suggest 
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the existence of a threshold in the rat model of OIR, such that a small change in blood 
oxygen profile triggers a disproportionate increase in subsequent neovascularization, 
which is accompanied by more dramatic changes of retinal VEGF level than VEGFR-2 
or PEDF level. If a similar threshold exists for humans, it could explain why some 
oxygen-treated premature infants develop retinopathy and others do not, despite similar 
gestational ages, birth weights and clinical courses. 
 
2.2 Introduction 
Several lines of evidence indicate that the progression of pathologic and physiologic 
angiogenesis is tightly controlled by a balance of pro-angiogenic and anti-angiogenic 
stimuli (55,56). VEGF stimulates endothelial cell proliferation and tube formation in 
vitro and is a major pro-angiogenic factor in vivo (57-60). Elevated levels of VEGF have 
been associated with animal models of, as well as humans affected with, ocular 
vasoproliferative disease (12,55,58,61). VEGF binds and activates two receptor tyrosine 
kinases, VEGFR-1/Flt-1 and VEGFR-2/KDR/Flk-1 (60). Experimental evidence suggests 
that VEGFR-2 contributes to the angiogenic phenotype by stimulating the MAP kinase 
pathway necessary for endothelial cell proliferation, an essential component of 
angiogenesis (62).  
 PEDF, originally isolated from the conditioned media of retinal pigment epithelial 
cells, displays neurotropic activity and is one of the most potent naturally occurring 
inhibitors of angiogenesis (63-65). PEDF inhibits endothelial cell proliferation in vitro 
and blood vessel growth in the eye (56). PEDF inhibits VEGF induced corneal 
neovascularization (65) and pathologic retinal angiogenesis in ischemia-induced 
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retinopathy of the mouse (66). Evidence to date suggests that PEDF manifests its anti-
proliferative effects by promoting endothelial cell apoptosis (67).  
ROP is a potentially blinding disease generally restricted to low birth weight infants 
sustained by oxygen therapy (6,68). The pathogenesis of human ROP is biphasic, starting 
with vasoattenuation related to hyperoxygenation of the neonatal retina, followed by 
retinal vasoproliferation (69). Dysregulated angiogenesis is constitutive of the 
vasoproliferative phase leading to the growth of retinal blood vessels through the inner 
limiting membrane into the vitreous cavity. This preretinal growth of vessels can lead to 
vitreous hemorrhage and tractional retinal detachment (70). A rat model has been 
developed that approximates the pathology of ROP and is reliable in terms of the 
development of this vasoproliferative response (71). The model consists of exposing 
newborn rat pups to alternating periods of hyperoxia and hypoxia. In a previous study, 
several exposure protocols were investigated and resulted in variable levels of disease 
incidence and severity (72). In particular, two very similar exposure protocols yielded 
widely disparate pathologic outcomes. One protocol involved exposing newborn rat pups 
to alternating periods of 45% oxygen (hyperoxia) and 12.5% oxygen (hypoxia), and in 
the other the oxygen levels were alternated between 40 and 15% (Figure 2.1). The 
‘45/12.5%’ exposure led to significantly greater disease incidence and severity than the 
‘40/15%’ treatment, despite the modest difference in the oxygen concentrations between 
the two exposure protocols.    
In this study we repeated these two oxygen treatments, and again observed highly 
significant differences in pathology between the two groups of rats. We then measured 
the VEGF, VEGFR-2 and PEDF retinal protein levels over time post-exposure to 
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Figure 2.1. A real-time plot of the 45/12.5 and 40/15% oxygen exposure regimen. 
Arrows designate times at which rats were sacrificed and analyzed. 
determine if the disproportionate differences in pathology between these two exposure 
paradigms could be related to differences in protein levels of the pro-angiogenic VEGF 
and VEGFR-2 and/or the anti-angiogenic PEDF.  
 
2.3 Materials and Methods 
 
Oxygen treatment 
Within 4 hr after birth, normalized litters of 16 Sprague-Dawley rat pups each were 
placed with nursing dams in Isolette® infant incubators, and subjected to one of two 
similar variable oxygen exposure protocols. The first was performed by cycling newborn 
rats between 40% oxygen for 24 hr and 15% oxygen for 24 hr for seven cycles and is 
referred to as the 40/15% protocol. The second protocol was similar except the hyperoxic 
episodes were 45% oxygen and the hypoxic episodes were 12.5% oxygen and is referred 
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to as the 45/12.5% protocol (Figure 2.1). The term ∆FiO2 used in Tables 2.1 and 2.2 
designates the difference in the two oxygen concentrations to which a treatment group 
was subjected, applying the units of fraction of inspired oxygen (i.e. ∆FiO2 = 0.25 for 
exposure to alternating 40 and 15% oxygen). Use and treatment of animals conformed to 
the Declaration of Helsinki principles.  
 
Table 2.1. Body weights of newborn rat pups after variable oxygen treatment.  
* Significantly different between 40/15 and 45/12.5% treatments, p < 0.05.  
** Significantly different between room air and both oxygen-treated groups, p < 0.05. 
 
  Body weights (g) (mean ± SD) 
Treatment (sample size) ∆FiO2 Day 14(0) Day 14(2) Day 14(6) 
40/15% (n = 20) 
 
45/12.5% (n = 24) 
 
Room air (n = 8) 
0.250 
 
0.325 
     21.7 ± 3.2 
 
     19.8 ± 1.3 
 
     25.9 ± 2.3** 
     29.6 ± 2.7 
 
     26.0 ± 2.1* 
 
     33.7 ± 1.6** 
     35.3 ± 5.0 
 
     33.2 ± 5.3* 
 
     45.6 ± 3.2** 
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Table 2.2. Effects of variable oxygen treatments on retinopathy. 
40/15 and 45/12.5% treatments were compared with each other. The percentages of the retina that is avascular were compared within 
each method, not between methods. * p < 0.05, ** p < 0.005. 
 
Retinal avascular area (% of total retinal area) (mean ± SD) Retinopathy  
Treatment (sample size) 
 
∆FiO2
 
Method Day 14(0) Day 14(2) Day 14(6) Incidence (%)  Severity (clock hours)
40/15% (n = 68) 
 
 
 
45/12.5% (n = 57) 
0.250 
 
 
 
0.325 
ADPase 
 
FITC 
 
ADPase 
 
FITC 
         8.3 ± 4.8 
 
       14.6 ± 6.6 
 
       15.7 ± 6.1** 
 
       23.8 ± 4.7* 
         3.5 ± 3.5 
 
         6.6 ± 4.4 
 
       11.1 ± 7.4** 
 
       13.4 ± 7.2* 
        0.1 ± 0.7 
 
        2.2 ± 1.5 
 
        2.6 ± 4.3** 
 
        5.8 ± 3.0 
        13.6 
 
 
 
78.3** 
Median 
 
Range 
 
Median 
 
Range 
0 
 
0 - 2 
 
2** 
 
0 - 9 
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Tissue histochemistry 
Animals from the 40/15 and 45/12.5% treatment groups were removed to room air 
after the 14th day of oxygen treatment, hereafter referred to as day 14(0). The degree of 
retinal avascularity of animals from the two exposure groups was measured at day14(0) 
and at 2 and 6 days post oxygen exposure, hereafter referred to as day 14(2) and 14(6), 
respectively. The retinal avascular areas were assessed by two methods: visualization of 
the retinal vasculature using infusion of fluorescein isothiocyanate (FITC)-conjugated 
dextran and adenosine diphosphatase (ADPase) staining (Figure 2.2). Animals from each 
exposure group were deeply anesthetized by isoflurane (Baxter, Deerfield, IL) inhalation. 
Right retinas were extruded for VEGF ELISA assay and Western blot analysis, and the 
central retinal artery and vein were clamped with hemostats. Then 40 µl of a calcium- 
and magnesium-free phosphate-buffered saline (PBS; Gibco, Rockville, MD) solution 
containing 9.0 mg of FITC-dextran, average molecular weight of 145 000 Da (Sigma, St. 
Figure 2.2. Demonstration of retinal avascular area assessed by ADPase staining and 
FITC-dextran infusion. The retina was harvested from the 45/12.5% oxygen-treated 
group on day 14(2). 
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Louis, MO), was infused through the left ventricle as previously described (71). The rats 
were sacrificed by decapitation and the left neural retinas were dissected and flat-
mounted. After evaluation of the retinal avascular area (see below), the same retinas were 
then placed in 10% (v/v) neutral buffered formalin (NBF). The 10% (v/v) NBF solution 
was prepared by dissolving 50 ml of a 37% formaldehyde solution (Fisher, Fair Lawn, 
NJ) in PBS to a total volume of 500 ml. The vasculature of each retina was stained using 
a histochemical method for detecting ADPase, according to a previously described 
procedure (73) adapted for use here (74). The stained retinas were then whole-mounted 
onto slides.  
 
Assessment of retinal avascularity and pathology 
After FITC-dextran infusion, images of flat-mounted retinas were observed with an 
Olympus fluorescence microscope (Olympus, Melville, NY) and captured digitally with a 
Polaroid DMC digitizing camera (Polaroid, Cambridge, MA) coupled to a G4 Macintosh 
computer (Apple, Cupertino, CA) utilizing Adobe Photoshop 5.0 (Adobe, San Jose, CA). 
After ADPase staining, the retinal avascular areas were re-evaluated. Images of the 
ADPase-stained retinas were digitized and captured in the same format as described 
above, except that a zoom stereomicroscope with an illumination base (Olympus) was 
used. The vascularized retinal areas and the total retinal areas of all retinal images were 
traced on the computer monitor face with an interactive stylus pen (FT Data Systems, 
Stanton, CA). The operator was masked with respect to the treatment. The vascularized 
retinal areas and the total retinal areas were converted from pixels to mm2 with image 
analysis software (Enhance 3.0; Microfrontier, Des Moines, IA). Then the retinal 
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avascular areas were calculated and the values are expressed as the percentage of total 
retina for each treatment group (mean ± SD) at each time point for each of the two 
staining methods. The retinas of age-matched room air controls were fully vascularized. 
Abnormal preretinal neovascularization was assessed using the clock hour method 
previously described by others and us (62), using flat-mounted ADPase stained retinas 
dissected on day 14(6). Three trained observers evaluated the number of clock hours with 
abnormal blood vessel growth for each retina. The data were averaged from the three 
separate determinations for each retina and are expressed in values varying from 0 (no 
pathology) to 12 (involvement of entire retinal circumference). The retinas of age-
matched room air rats showed no pathology. 
 
VEGF enzyme immunoassay 
Retinal tissues from the right eyes of animals sacrificed on day 14(0), 14(2) and 14(6) 
were frozen at -80°C immediately after extrusion. They remained frozen for 2-18 hr. The 
thawed retinas were sonicated in tris-buffered saline (TBS) containing protease and 
phosphatase inhibitors (50 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, 1 mM PMSF, 1 
µg/ml aprotinin, 1 µg/ml leupeptin, 1 µg/ml pepstatin A, 1 mM Na3VO4, 1 mM NaF, PH 
7.4) (Sigma). After centrifugation, supernatants were collected for experiments. The 
protein concentration of samples was measured by the bicinchoninic acid assay (BCA; 
Pierce, Rockford, IL). A VEGF colorimetric sandwich ELISA kit (R&D Systems, 
Minneapolis, MN) was used for retinal VEGF determination according to the 
manufacturer's instructions. The final mass of retinal VEGF was standardized to total 
retinal protein. 
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Western blot analysis 
Polyclonal anti-VEGFR-2 antibody was purchased from Santa Cruz Biotechnology 
(Santa Cruz, CA). Polyclonal anti-PEDF antibody was purchased from BioProducts 
Maryland (Middletown, MD). Monoclonal antibody against β-actin, which was used as a 
gel loading control, was purchased from Sigma. Anti-rabbit or mouse HRP antibody 
(Promega, Madison, WI) was used as a secondary antibody. Retinal homogenates above 
were resolved by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) using 10% SDS-PAGE minigels (Bio-Rad, Hercules, CA). Proteins were then 
transferred to 0.2 µm nitrocellulose membrane (Bio-Rad). After incubation in the 
blocking buffer, TBS with 0.1% Tween-20 (Sigma) and 5% nonfat dry milk (Bio-Rad), 
for 30 min at room temperature, membranes were rinsed with TBS and incubated with 
the primary antibody in the blocking buffer overnight at 4°C. Then, membranes were 
washed with TBS and incubated with the secondary antibody in blocking buffer for 2 hr 
at room temperature. After thorough washing, the proteins were visualized with enhanced 
chemiluminescence (Amersham, Piscataway, NJ). Membranes were also stripped and 
reprobed for β-actin. Experiments were repeated three times. 
 
Data analysis 
Data were analyzed with Stat View software (Abacus Concepts, Berkeley, CA). The 
ANOVA statistical test was used to analyze parametric data of animal body weight and 
retinal VEGF concentration. Digitized images of Western blots were subjected to 
quantification with National Institutes of Health (NIH) Image software (Bethesda, MD). 
Raw densitometry values of VEGFR-2 and PEDF were normalized against that of β-
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actin. These data were subsequently analyzed with the ANOVA test. The percentages of 
the retina that is avascular were converted with the arcsine transformation and 
subsequently analyzed with the Kruskal-Wallis statistical test. The retinopathy data 
assessed by the clock-hour method were analyzed with the non-parametric Mann-
Whitney test. For each test, p < 0.05 was considered significant.  
 
2.4 Results 
 
Body weight 
Room air animals had significantly higher body weight than either of the oxygen-
treated groups at all three ages tested (Table 2.1). The body weight of the 40/15% group 
was significantly higher than that of the 45/12.5% group on day 14(2) and 14(6). 
However, there was no significant difference between them on day 14(0). 
 
Retinal avascularity 
As shown in Table 2.2, the average percentage of the retina that is avascular for the 
45/12.5% treatment group was consistently and significantly higher (p < 0.005) than that 
of the 40/15% treatment group at each of the three time points examined using ADPase 
staining. Statistical significance was also achieved at day 14(0) and 14(2) using FITC-
dextran infusion (p < 0.05). ADPase staining demonstrated a similar pattern of retinal 
avascular area as FITC-dextran infusion (Figure 2.2), but yielded values for the average 
percentage of avascular retinal area that were consistently lower than FITC-dextran 
infusion (Table 2.2). This is reasonable, as the FITC-dextran infusion technique assesses 
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retinal area associated only with the perfused vasculature, while the ADPase surface stain 
marks both perfused and non-perfused vessels. The retinas of rat pups raised in room air 
already reached complete vascularization on day 14(0). 
 
Retinal neovascularization 
Retinal neovascularization was assessed on day 14(6). A significant difference in 
incidence and severity between the 45/12.5 and 40/15% treatment groups was observed 
(Table 2.2, Figure 2.3). In the 45/12.5% treatment group, 78.3% of the rat pups displayed 
some level of preretinal neovascularization compared to 13.6% in the 40/15% treatment  
group. The level of severity, as measured by clock hours containing preretinal 
neovascularization, showed a range of 0 - 9 and a median of 2 for the 45/12.5% group 
Figure 2.3. Comparison and demonstration of retinopathy in ADPase-stained retinas 
from rats treated with the 45/12.5 or the 40/15% oxygen exposure regimen. Retinas were 
harvested on day 14(6). The 45/12.5% rats had larger avascularity and more retinopathy 
(arrows) than 40/15% animals.
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and a range of 0 - 2 and a median of 0 for the 40/15% group (p < 0.005). There was no 
retinal pathology observed in rat pups raised in room air.  
 
Retinal VEGF concentration 
As shown in Figure 2.4, on day 14(0), retinal VEGF level in the 45/12.5% group is as 
high as 1.5-fold of that in the 40/15% group (p = 0.005). Both are significantly higher 
than room air controls (p < 0.005). On day 14(2), retinal VEGF concentrations of both 
oxygen-treated groups decreased, compared to those of day 14(0). There was no 
significant difference between the 40/15% group and room air control. However, VEGF 
level in the 45/12.5% group remained significantly higher level, about 1.8-fold of that of 
Figure 2.4. Retinal VEGF levels in rats treated with the 45/12.5 (n = 24) or the 40/15% 
(n = 20) oxygen exposure regimen, and in room air controls (n = 8). Data on each time 
point tested were compared between the 45/12.5 and 40/15% treatments, and between 
room air control and 45/12.5 or 40/15% treatment. Significant differences are 
demonstrated with p value. 
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the 40/15% group (p < 0.05). On day 14(6), there was no significant difference between 
any of the experimental groups. There was also no significant difference in retinal VEGF 
levels in room air rat pups over the time-course of this experiment. 
 
Retinal VEGFR-2 and PEDF expression 
Western blot analysis of whole retinal lysates shows that the VEGFR-2 levels in the 
45/12.5 and 40/15% groups were not significantly different from each other at any of the 
time points tested, either by direct comparison of  β-actin-normalized densitometry values 
(Figure 2.5, a and b) or after further normalization to retinal vascular area (data not 
shown). The latter method was based upon the notion that the greater the vascular area 
and density, the greater the expected level of VEGFR-2 in whole retinal lysate. Previous 
studies showed a significant increase of VEGFR-2 in OIR (75,76). In this study, whole 
retinal VEGFR-2 level in the room air group on day 14(0) was significantly higher than 
that in either oxygen-treated group, likely because the substantially greater vessel 
coverage and density in room air controls masked any of the local differences of VEGFR-
2 in room air and oxygen-treated eyes. Retinal PEDF levels did not show significant 
differences among all three groups in the three tested points (Figure 2.5, a and c). 
 
2.5 Discussion 
The incidence and severity of ROP in premature human infants is highly correlated 
with variability in arterial blood oxygen levels during oxygen therapy (77-79). The partial 
pressure of oxygen in arterial blood can fluctuate rapidly in sick premature infants, 
leading to alternating episodes of severe and extended hyperoxemia and hypoxemia (79). 
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Figure 2.5. Retinal VEGFR-2 and PEDF protein expression levels in whole retinal 
lysates from rats treated with the 45/12.5 or the 40/15% oxygen exposure regimen, and 
from room air controls. a, Western blots demonstrate retinal VEGFR-2 and PEDF protein 
expression level. b, Densitometry analysis reveals no significant difference of VEGFR-2 
levels between the 45/12.5 and 40/15% groups on day 14(0), 14(2), and 14(6). *, 
significantly different from room air control, p < 0.05. c, Densitometry analysis shows 
retinal PEDF levels of oxygen-treated rats and room air controls were not significantly 
different from each other at all three time points tested under ANOVA statistical test, p > 
0.05. 
Frequently, these events are related to the infant's underlying disease (e.g. patent ductus 
arteriosus, apnea, metabolic acidosis and bronchopulmonary dysplasia), but they may 
also be simply the result of routine medical and nursing intervention (79).  
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Mimicking these conditions, newborn rats that experience alternating cycles of 
ambient hyperoxia and hypoxia show a significant increase in the prevalence and 
consistency of the vasoproliferative response when compared to newborn rats that 
experience constant ambient hyperoxia or variable ambient hyperoxia (71,72,74). 
Furthermore, it has been previously shown that cyclic variation of 50 and 10% inspired 
oxygen translates into variable arterial blood oxygen levels in these rats which mimic the 
variable arterial blood oxygen levels of premature humans undergoing oxygen therapy in 
whom ROP is likely to develop (72). The results of these studies indicate that episodic 
ambient hypoxia during oxygen treatment promotes the production of a robust 
neovascular response in rats.     
The two exposure paradigms that were repeated in this study, namely 40/15 vs. 
45/12.5%, yielded disproportionate degrees of pathology despite the relatively small 
difference in oxygen concentrations used (Figure 2.1, Table 2.2). As before (72), the 
45/12.5% protocol resulted in significantly higher incidence and severity of pathology 
when compared to the 40/15% exposure protocol (see Section 2.4). To investigate 
possible mechanisms that might explain the observed difference in pathological 
outcomes, we measured the retinal levels of pro-angiogenic VEGF and VEGFR-2 and 
anti-angiogenic PEDF in animals from these two treatment protocols over time post-
oxygen exposure. The retinal VEGF levels of the 45/12.5% group were significantly 
higher on both day 14(0) (48%) and 14(2) (78%) than the 40/15% group. Although 
significant higher on day 14(0), retinal VEGF level in the 40/15% group on day 14(2) 
was not significantly different from that of the room air control. The VEGFR-2 and 
PEDF retinal levels of these two groups were not significantly different from each other 
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at any of the time points tested. Even though on day 14(2), PEDF in the 45/12.5% group 
trended towards difference from room air control and 40/15% animals, it is not 
significant under statistical test, p = 0.250 and 0.172 respectively. Based on these data, it 
is reasonable to suggest that the greater pathology observed in the 45/12.5% group is 
associated with a higher and longer retinal VEGF elevation observed post-oxygen 
exposure than in the 40/15% group. Additionally, VEGF, VEGFR-2, and PEDF were 
measured in whole retinal lysates. It is likely that although there may be significant local 
increase of retinal VEGF and VEGFR-2 levels (i.e. VEGFR-2 up-regulation in vascular 
tufts) (75,76) or possible local decrease of retinal PEDF level, in whole retinal lysates 
changes of VEGFR-2 or PEDF proved not as dramatic as that of VEGF. This may 
indicate a larger extent of global changes of retinal VEGF level than VEGFR-2 and 
PEDF levels. 
VEGF is induced by hypoxia (58). It is possible that the higher retinal VEGF levels in 
the 45/12.5% treatment group at the time of removal of these animals to room air on day 
14(0) are related to the episodes of more extreme ambient hypoxia (i.e. 12.5 vs. 15%) 
experienced by this group during oxygen treatment. The difference in retinal VEGF on 
day 14(2), however, may be related to the greater avascular area observed in the 
45/12.5% treatment group. It has previously been hypothesized that the retinal avascular 
area becomes hypoxic on removal to normoxia, stimulating the synthesis of hypoxia-
inducible factors such as VEGF (80-84). Therefore, the 45/12.5% group would likely 
produce more retinal VEGF post-oxygen exposure. 
Investigators have proposed that the dominant neovascular stimulus in oxygen 
induced proliferative retinopathies is produced post-oxygen exposure by the avascular 
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retina (5,6,81,85). There are data that are consistent with this view. For example, in a 
mouse model of OIR, post-oxygen retinal VEGF mRNA levels were 50% compared to 
room air controls and increased six-fold by 24 hr post-exposure (86). However, in our rat 
model with variable oxygen exposure, it is obvious that both oxygen treatment and post-
exposure retinal avascular area contribute to the onset of retinopathy. Although in this 
study it is not clear yet whether the high level of VEGF immediately after oxygen 
exposure is due to a cumulative effect of multiple episodes or simply one episode of 
hypoxia, robust neovascular stimulus is evident at the end of the oxygen treatment. This 
neovascular stimulus is even greater than the later one caused by retinal avascular area, 
since the retinal VEGF levels at 14(0) are about 2-fold of those at 14(2) in both 45/12.5 
and 40/15% groups. It is important to note that 65% of preterm infants that receive 
oxygen therapy develop threshold ROP during the course of the therapy (Dale Phelps, 
personal communication, information derived from the STOP ROP trial; 2004). Clearly, a 
pro-angiogenic stimulus may develop before removal to room air and play a significant 
role in the pathogenesis of ROP.  
In this study, similar oxygen exposure protocols resulted in significantly different 
pathologic outcomes that correlate with a difference in retinal VEGF levels in a rat model 
of OIR. Collectively, these data substantiate the notion that retinal VEGF levels may 
represent an index for the development of ischemia-induced retinal angiogenesis that may 
have bearing on human ROP. Furthermore, our studies suggest the existence of a 
threshold of variable oxygen concentrations in a rat model of OIR, which results in a 
disproportionate increase in subsequent neovascularization. Underlying the discrepancy, 
we observed a dramatic change of retinal VEGF level but not VEGFR-2 or PEDF level in 
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whole retinal lysates. If there is a similar event in human, this study may shed light on 
understanding why some premature infants develop ROP and others do not, even when 
the two experience similar clinical courses.  
This work was supported by NIH grants EY07533 and EY08126 (JSP) and a grant 
from Research to Prevent Blindness, Inc.
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3.1 Abstract 
VEGF-mediated retinal angiogenesis includes both VEGF induction and signal 
transduction cascades. To date, much more effort has been spent on understanding and 
intervening in VEGF downstream signaling than on the upstream induction pathway. In 
order to study the mechanism of retinal VEGF induction by ischemia-induced hypoxia, 
we have developed an in vitro model of VEGF induction in primary rat Müller cells. 
Primary and transformed, immortalized Müller cells were compared under this condition. 
Exposure to hypoxia (0% oxygen) for 24 hr consistently and significantly induced VEGF 
protein production by two-fold in primary Müller cells. Only mild impact on cell growth 
was observed. The hypoxia treatment also increased VEGF production in the transformed 
rMC-1 cell culture. However, cell growth retardation and death were obvious. Both 
primary Müller cells and rMC-1 cells showed no increase of glial fibrillary acidic protein 
(GFAP) expression after 24 hr of hypoxia treatment. The results suggest a practical 
method of using primary rat Müller cells as an in vitro model to study the VEGF 
induction pathway in ischemia-induced retinal angiogenesis. 
 
3.2 Introduction 
Retinal or subretinal angiogenesis is the characteristic pathologic event of diverse 
retinal diseases. For most, if not all, ischemia-mediated angiogenic retinal conditions, 
VEGF is implicated as a critical factor. VEGF is a potent angiogenic growth factor and 
vasopermeability factor with high specificity for endothelial cells (19). The onset of 
VEGF-mediated retinopathy is composed of two main episodes: upstream VEGF 
induction by ischemia-induced hypoxia and downstream VEGF signaling in vascular 
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endothelial cells. For a decade, extensive efforts have been made to identify VEGF-
related targets for pharmacologic intervention. Virtually all have been aimed at VEGF, its 
receptors or components of its signal transduction cascade. Much less effort has been 
spent on defining the retinal VEGF induction pathway or searching for potential 
therapeutic targets upstream from VEGF. 
Müller cells are the most abundant glial cells in the vertebrate retina and play 
important roles in maintenance of retinal extracellular homeostasis and metabolic support 
of neurons, as do astrocytes, oligodendrocytes, or ependymal cells in other parts of the 
central nervous system (87). In the retina, Müller cells are the main storage site for 
glycogen, principally obtaining ATP through glycolysis and consuming little oxygen 
(88). They are highly resistant to hypoxia and hypoglycemia. Müller cells are also the 
predominant VEGF secreting cell type when the retina experiences hypoxia (11,89). 
Thus, Müller cells are an appropriate venue for studies of the molecular basis of retinal 
VEGF induction by hypoxia.  
Recently developed methods for isolating and culturing Müller cells have provided 
better yield and purity allowing for their use in high throughput assays (90). Additionally, 
Dr. Vijay P. Sarthy and his colleagues successfully established an immortalized Müller 
cell line, rMC-1, which displays the Müller cell phenotype (91). rMC-1 cells were 
originally established and confirmed to facilitate gene expression studies in Müller cells. 
Their potential usage in studies of VEGF induction by hypoxia in vitro has not been 
defined.  
Herein, we report an optimal condition for VEGF induction by hypoxia in primary rat 
Müller cell cultures, and compare primary Müller cells and rMC-1 cells under this 
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condition. This method of VEGF induction in primary rat Müller cell cultures is well 
controlled, reproducible and quantifiable. We believe the model can serve as a ready 
venue for studies of the molecular basis of retinal VEGF induction or as a method to 
screen potential inhibitors for future therapeutic applications. 
 
3.3 Materials and Methods 
 
Cell culture 
All animals used in the study were cared for and handled according to the Association 
for Research in Vision and Ophthalmology (ARVO) Statement for the Use of Animals in 
Ophthalmic and Vision Research. Primary retinal Müller cell cultures were established 
from postnatal day 8 Long-Evans rat pups as previously described (90). Cells were grown 
in Dulbecco’s modified eagle medium (DMEM; Gibco) supplemented with 10% fetal 
bovine serum (FBS; Hyclone, Logan, UT) and 1X antibiotic-antimycotic solution 
(Sigma). This medium will be known as “growth medium” in the experiments described 
below. Cultures were maintained at 37˚C in a 5% CO2/95% air (20.9% oxygen) 
atmosphere (normoxic condition) in a humidified incubator. Passages from 3 to 5 were 
used for experiments. The identification of Müller cells was confirmed by 
immunocytochemical staining with a monoclonal antibody recognizing vimentin 
(DAKO, Carpinteria, CA), an intermediate filament protein normally expressed in Müller 
cells, and with polyclonal and monoclonal GFAP antibodies (DAKO).  
The Müller cell line, rMC-1, was a kind gift from Dr. Vijay P. Sarthy. The cell line 
was established by transfecting primary rat Müller cell cultures, isolated from Sprague-
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Dawley rats, with simian virus 40 (SV40). rMC-1 cells were reported to express both 
GFAP, a marker for reactive gliosis in Müller cells, and cellular retinaldehyde-binding 
protein, a marker for Müller cells in adult retina (91). rMC-1 cells were routinely cultured 
under the same condition as primary Müller cells. 
 
Hypoxia exposure 
Primary rat Müller cells or rMC-1 cells were seeded in 6 cm-Petri dishes at the same 
density and maintained at normoxic condition to 80% subconfluence with growth 
medium. On experiment day, cells were washed and supplemented with fresh culture 
medium, 4 ml per 6 cm-Petri dish. The cells were subjected to different hypoxic 
conditions for 24 hr. The anoxic condition (about 0% oxygen) with a CO2-enriched 
environment was generated with BBL™ GasPak Pouch™ system (Becton Dickinson, 
Sparks, MD). Normoxic and other hypoxic conditions, oxygen concentrations ranging 
from 20.9% to 2.5%, were generated with an Isotemp laboratory CO2 incubator with O2 
control (Kendro Laboratory, Asheville, NC). Appropriate humidity and 5% CO2 were 
maintained at all times. 
 
VEGF and protein quantification 
Culture media from experimental dishes were collected and assayed for VEGF 
concentration with a colorimetric sandwich ELISA kit (R&D Systems) according to the 
manufacturer’s instructions. The assay recognizes the 164 amino acid residue form of 
mouse VEGF, which shares 98% amino acid sequence identity with its rat homolog (92). 
Cells were washed with cold calcium- and magnesium-free PBS (Gibco) and lysed with 
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cold lysis buffer (50 mM Tris-HCl, 150 mM NaCl, 1% NP-40, 0.25% sodium 
deoxycholate, 1 mM EDTA, 1 mM PMSF, 1 µg/ml aprotinin, 1 µg/ml leupeptin, 1 µg/ml 
pepstatin A, 1 mM Na3VO4, 1 mM NaF, PH 7.4) (Sigma). Cell lysates were centrifuged 
at 5000 g for 15 min at 4˚C and protein concentrations were determined with a BCA 
protein assay kit (Pierce). The amount of VEGF (pg/ml) in culture media was normalized 
to total protein concentration (mg/ml) of cell lysates. Thus, it resolved the variation of 
VEGF production due to different cell densities. VEGF induction was designated as the 
ratio of normalized VEGF production (pg/mg) of hypoxia-treated cells to that of 
normoxia controls. Data were subjected to ANOVA statistical test using Stat View 
software (Abacus Concepts). All experiments were independently repeated at least three 
times.  
 
Immunocytochemistry 
Primary rat Müller cells or rMC-1 cells were seeded on coverslips for 2 days. 
Medium was freshly changed and cultures were then exposed to hypoxia with BBL™ 
GasPak Pouch™ system or maintained in normoxia for 24 hr. After washing with PBS, 
cells were fixed with 3% paraformaldehyde (Sigma) for 30 min, permeabilized in 0.1% 
Triton X-100 (Sigma) for 5min, and blocked in 1% bovine serum albumin (Jackson 
Immunoresearch Lab., West Grove, PA) for 10 min. Coverslips were incubated with 
primary antibodies at appropriate working dilutions for 30 min. FITC-conjugated goat 
anti-mouse IgG antibody and/or rhodamine red-X (RRX)-conjugated goat anti-rabbit IgG 
antibody (Jackson Immunoresearch Lab) were used as secondary antibodies. Samples 
were viewed with an Olympus fluorescence phdemicroscope (Olympus). 
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3.4 Results 
 
The optimal hypoxic condition for VEGF induction in the primary rat Müller cell 
culture 
 
Normoxic cell culture conditions constitute a higher oxygen concentration than that 
normally found in the retina (8). Primary rat Müller cells spontaneously secret VEGF, 
even in normoxia, at a level of 215.32 ± 56.47 pg/mg after 24 hr incubation. We did not 
detect VEGF using the ELISA assay in fresh DMEM growth medium. When oxygen 
concentration was reduced to about 0%, a two-fold increase in VEGF production over the 
normoxia control group was induced (p < 0.05) (Figure 3.1). Longer exposure periods 
augmented the magnitude of the difference, data not shown. Oxygen concentrations of 
2.5% or higher failed to induce significantly higher VEGF protein production than 
normoxia by the 24-hour exposure regimen. Under the various hypoxic exposure 
conditions, there were no significant morphologic changes of primary Müller cell cultures 
observed by light microscopy.  
 
Comparison of primary rat Müller cells and rMC-1 cells under the hypoxic condition 
 
Under normoxic conditions, rMC-1 cells proliferated faster and displayed smaller 
cellular size than primary Müller cells. Like primary cells, rMC-1 cells also 
spontaneously secreted VEGF, at a level of 202.65 ± 39.71 pg/mg after 24 hr incubation, 
which was not significantly different from VEGF production by primary Müller cells in 
normoxia (p > 0.05).  
rMC-1 cells appeared to be more susceptible to oxygen starvation than primary 
cultures. After hypoxia (0% oxygen) exposure for 24 hr, rMC-1 showed substantial cell 
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Figure 3.1. Comparison of primay rat Müller cells and rMC-1 cells under hypoxia. Cells 
were exposed to hypoxia (Hypo, 0% oxygen) or normaxia (Nor) for 24 hr. a, The impact 
of hypoxia on total protein mass. Results are the ratio of protein mass of hypoxia-treated 
samples to that of normoxia-maintained controls. b, VEGF induction by hypoxia. 
growth retardation. Some cells rounded up and detached from the culture surface. The 
total protein mass of attaching cells, which is presumed to correlate with the amount of 
live cells, in hypoxia-treated rMC-1 cultures was 35.4% (p < 0.05) of that of normoxia-
maintained controls. Primary Müller cell cultures were less affected by hypoxia; floating 
cells were rare. Total protein mass of hypoxia-treated samples was 84.0% (p < 0.05) of 
that of normoxic samples (Figure 3.1a).  
Nevertheless, hypoxia did induce VEGF production in rMC-1 cells. After exposure to 
hypoxia (0% oxygen) for 24 hr, the amount of VEGF in the medium (pg/ml) of rMC-1 
cultures significantly increased by about two-fold compared to that of normoxia-
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maintained controls, despite the significantly smaller amount of live cells. When 
normalized to the total protein mass, VEGF production in hypoxia was 5.7-fold (p < 
0.05) of that in normoxia, while a moderate increase of 2.0-fold (p < 0.05) was observed 
in primary cultures (Figure 3.1b).  
A generalized increase of GFAP expression had been suggested to be a form of 
reaction in Müller cells to injuries in vivo (90). Thus, we further tested the impact of 
hypoxia (0% oxygen) on GFAP expression in primary Müller cells and rMC-1 cells. 
Consistent with previous reports (90), primary cultures were stained very weakly for the 
presence of GFAP by a polyclonal antibody. A stronger staining of nuclei was an 
apparent artifact of the polyclonal probe, since immunoreactivity was omitted when a 
monoclonal antibody was used. rMC-1 cells were also weakly stained by GFAP 
antibodies, as previously reported (91). After 24 hr exposure to hypoxia (0% oxygen), 
neither primary cultures nor rMC-1 cells showed a significant increase of the intensity in 
GFAP staining as compared to cells maintained in normoxia (Figure 3.2). Anti-vimentin 
staining showed no obvious morphology changes in either cell types.  
 
3.5 Discussion 
As predominant glial and VEGF secreting cells in the retina, Müller cells are superior 
to other retinal VEGF-secreting cell types for studying hypoxia-induced VEGF 
production pathways (93). Müller cells can respond to direct hypoxia insults by 
increasing VEGF production in monolayer cultures. Exposing primary rat Müller cells to 
oxygen concentrations of 0% for 24 hr consistently and significantly induces VEGF 
expression. The magnitude of the response can be potentially extended by longer 
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Figure 3.2. Immunocytochemistry analysis of GFAP expression in primary rat Müller 
cells and rMC-1 cells under hypoxia. Cells were exposed to hypoxia (0% oxygen) or 
maintained in normoxia for 24 hr. Cells were co-stained for GFAP and vimentin. GFAP 
is shown by RRX-labeling; vimentin is shown by FITC-labeling.
exposure periods, which will create an even greater window for characterizing or testing 
inhibitors of the process. Our finding that GFAP up-regulation was not induced by 
hypoxia exposure in vitro differs from published findings using in vivo models (90). This 
suggests that either the hypoxic condition is not stressful enough for GFAP expression, or 
that neuron-glial interactions are required for GFAP activation in Müller cells’ response 
to hypoxia. Different from detecting VEGF messenger RNA by Northern blot, VEGF 
production in culture medium can be conveniently and accurately quantified by ELISA 
assay. Vulnerability of primary Müller cells to hypoxia is minimal under these exposure 
conditions. This assay can be utilized for quantitative studies of VEGF induction 
pathways by hypoxia, and as a venue to screen potential inhibitors for therapeutic 
applications.  
In addition to its utility in gene expression studies, rMC-1 cells may be used for 
studying VEGF induction by hypoxia, particularly because secretion of VEGF by rMC-1 
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cells can be substantially induced by hypoxia. However, caution is warranted for several 
reasons. First, rMC-1 is an immortalized cell line derived from primary rat Müller cells 
by SV40 transfection. The phenotype of the cells is clearly different from that of primary 
cells. Secondly, rMC-1 cells are much more dependent on oxidative metabolism than 
primary cultures. Primary Müller cells obtain ATP principally from glycolysis and are 
highly resistant to oxygen starvation (88). However, rMC-1 cells display substantial cell 
growth retardation and even cell death upon exposure to a hypoxic condition which 
primary cells can tolerate well. In addition, the elevated capability of VEGF induction by 
hypoxia in rMC-1 also indicates the potential modifications of the molecular mechanism 
underlying the induction pathway.  
As these cells become more widely used in scientific research, the advantages and 
disadvantages of both primary Müller cells and rMC-1 cells as experimental tools will be 
further characterized. Elucidation of the VEGF induction pathway and its utility in the 
development of therapeutic strategies will further improve the understanding and 
intervention of the onset of retina angiogenesis. 
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4.1 Abstract 
Widely coexpressed SFK members Src, Fyn and Yes are involved in various cellular 
events, often acting downstream of receptor tyrosine kinases, such as VEGF receptors. 
They are well known for their functional redundancy; any unique features remain largely 
undefined. Utilizing RNA interference (RNAi), we have selectively knocked down Src, 
Fyn and Yes in human retinal microvascular endothelial cells (RMECs). Cells with single 
SFK knockdown showed that all three kinases were required for VEGF mitogenic 
signaling. VEGF-induced cell migration was significantly increased in Fyn-deficient cells 
and decreased in Yes-deficient cells. Selective interference of Fyn, but not Src or Yes, 
impaired VEGF-induced tube formation in human RMECs. Cells in which all three SFKs 
were targeted showed significant inhibition of all three cellular events. In addition, 
interference of Src, Fyn and Yes did not affect the anti-apoptotic effect of VEGF in 
human RMECs, as determined by DNA fragmentation analysis. These results provide 
direct evidence that Src, Fyn and Yes maintain distinct properties in the regulation of 
VEGF-mediated endothelial cell events.   
 
4.2 Introduction 
Angiogenesis is the process of new blood vessel formation from preexisting 
capillaries. It is not only fundamental to many physiological events, but also to the partial 
or characteristic pathology of a broad range of disease conditions, such as cancer, chronic 
inflammation (e.g. rheumatoid arthritis) and cardiovascular diseases (e.g. atherosclerosis) 
(94,95). Pathological retinal angiogenesis is the leading cause of severe vision loss and 
irreversible blindness in developed countries, affecting people of all ages (2,3). Despite 
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their tissue specificities, all types of angiogenesis share common features allowing for 
application of findings between systems. 
VEGF has been shown to play a major role in the initiation and regulation of both 
physiological and pathological angiogenesis in various tissues (2,60). VEGF is a 45kDa 
heparin-binding growth factor (20,57). Initially known as vascular permeability factor 
(96), VEGF has a profound impact on multiple facets of endothelial cell function, such as 
promoting cell growth (57,97), migration (38), and survival (39,98). These biological 
effects are mediated through the high affinity tyrosine kinase receptors, VEGFR-1 (flt-1) 
and VEGFR-2 (KDR/flk-1) (32-34,99).  
Eliceiri and colleagues reported that, in vivo, SFKs were selectively required in 
VEGF-, but not basic fibroblast growth factor-, mediated angiogenesis (46). Other groups 
demonstrated that SFKs signal upstream of important intermediates, such as PLC-γ (100) 
and FAK (47), and are involved in multiple VEGF-mediated endothelial cell events (46-
48,101). 
SFKs are nonreceptor membrane-attached protein tyrosine kinases. They form 
complexes with various receptors and intracellular substrates, influencing a broad 
spectrum of cellular events (43). The SFK members Src, Fyn and Yes are coexpressed in 
many tissues, including vascular endothelium (43-45). These closely related SFKs are 
well known for their functional redundancy. Deficiency in one SFK member can be 
compensated by other SFKs that are coexpressed (43,51). However, their unique features 
remain largely undefined. Eliceiri and colleagues showed that Src- or Yes-, but not Fyn-, 
deficient mice displayed impaired VEGF-induced vascular permeability (46). Systemic 
administration of PP1 (a broad spectrum SFK-inhibitor) to mice demonstrated the 
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potential to prevent secondary tissue damage due to increased VEGF-mediated vascular 
permeability [e.g. in the pathophysiology of stroke (52)]. In the eye, VEGF-mediated 
vascular permeability is notoriously responsible for extravasation in both neovascular and 
non-neovascular retinopathies (3,53,54). Thus, inhibition of SFKs in the eye may benefit 
the outcomes of many types of ocular edema. Before SFKs can be reasonably targeted for 
intervention in VEGF-mediated retinal angiogenesis and vascular permeability, the 
biological functions of the family members and their roles in pathological events must be 
defined. Optimal strategies will be aimed at those family members that actively 
contribute to the pathogenesis of a disease, while avoiding others that are essential for 
maintaining physiological functions. 
Success of RNAi in mammalian cells (102) suggested that this method could be a 
reasonable approach to target the highly homologous Src, Fyn, or Yes for specific 
inhibition. RNAi is a process of sequence-specific, post-transcriptional gene silencing, 
which is widely recognized as a natural mechanism for cellular protection and cleansing 
in most eukaryotes (103). In mammalian cells, effective RNAi is mediated by double-
stranded 21- or 22-nucleotide small interfering RNAs (siRNAs) (102). Although double 
knockdown of two proteins by siRNAs in mammalian cells was demonstrated (104), 
other studies showed that different siRNAs competed with one another when 
simultaneously introduced into cells, reducing the silencing effect of either individual 
sequence (105,106). The implication is that the RNAi machinery may be saturable (107). 
Thus, to achieve a successful multiple knockdown, careful titration and control of siRNA 
concentration is necessary. 
Here, we demonstrate that human RMECs are susceptible to specific-gene RNAi.  
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Synthetic siRNA-mediated interference of Src, Fyn and Yes result in clear phenotypic 
changes in VEGF-induced endothelial cell events. Our results provide direct evidence of 
the differential properties of Src, Fyn and Yes in the regulation of VEGF signal cascades. 
Further characterization may facilitate selective targeting of individual SFK member(s) 
for intervention in VEGF-mediated pathological angiogenesis and vascular permeability. 
 
4.3 Materials and Methods 
 
Cell culture 
Primary cultures of human RMECs (Cell Systems, Kirkland, WA) from the 5th to the 
6th passages were used in all experiments. Culture vessels were coated with 0.1% gelatin 
(Sigma) in calcium- and magnesium-free PBS (Gibco). Cells were incubated at 37˚C with 
5% CO2 in endothelial growth medium (EGM; Cambrex, East Rutherford, NJ), 
supplemented with 10% FBS (Hyclone), referred to as growth medium. When 
experimental conditions required a serum and growth factor-free (SF) medium, MCDB- 
131 medium (Sigma) containing 1X antibiotic-antimycotic solution (Sigma) was used. 
 
siRNA transfection 
Upon 80% confluence, human RMECs were trypsinized with the ReagentPack™ 
subculture kit (Cambrex). For each transfection, siRNAs were electroporated into 5 x 105 
cells using a human lung microvascular endothelial cell Nucleofector™ kit (Amaxa, 
Gaithersburg, MD) and a Nucleofector™ device (Amaxa) according to the 
manufacturer’s instructions. Immediately after electroporation, cells were resuspended in 
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prewarmed antibiotics-free EGM containing 10% FBS. Cells were seeded simultaneously 
to analyze protein levels and VEGF-induced cellular events. Cells began to attach to 
culture vessels within one hour after electroporation and, 24 hours later, about 80% of the 
seeded cells were viable. 
Four siRNAs targeting human Src mRNA were designed in conformity with The 
siRNA User Guide (108) utilizing Whitehead Institute’s siRNA search engine. The 
sequences corresponding to Src cDNA were: the 5΄ untranslated region (UTR), 
AAGCAACTTGCCCAGCTATGA; the SH2 domain, 
AAAGTGAGACCACGAAAGGTG; a region of the tyrosine kinase domain, 
AAGCTGGTGCAGTTGTATGCT; and a region surrounding tyrosine 419 of the 
tyrosine kinase domain, AAGACAATGAGTACACGGCGC. Each siRNA duplex was 
BLAST-searched against EST libraries to ensure that only one gene was targeted. Then, 
siRNAs were chemically synthesized by Qiagen (Valencia, CA) with symmetric 3΄ dTdT 
overhangs. Four additional siRNA duplexes with symmetric 3΄ UU overhangs targeting 
human Src mRNA were purchased from Dharmacon (Lafayette, CO). These were 
siRNAs targeting the conjunctional region between the SH2 domain and the tyrosine 
kinase domain, CGTCCAAGCCGCAGACTCA, and three regions of the tyrosine kinase 
domain, TGCCTCAGCTGGTGGACAT, CCTCAGGCATGGCGTACGT and 
GAGAACCTGGTGTGCAAAG (Figure 4.1a).  
The Fyn siRNA duplex (109) with symmetric 3΄ dTdT overhangs, corresponding to 
the SH2 domain of Fyn cDNA, AAAGATGCTGAGCGACAGCTA, was chemically 
synthesized by Qiagen (Figure 4.1a). Validated synthetic Yes siRNA (Figure 4.1a), β-
actin siRNA, and nonsense control siRNA were purchased from Ambion (Austin, TX). 
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 a. 
b. 
 
c.
d. 
Control siRNA Src siRNA 
Figure 4.1. siRNAs mediate specific gene-downregulation of Src, Fyn or Yes in human 
RMECs. a, Schematic of the domain structure of Src, Fyn and Yes mRNAs. Small black 
bars indicate the relative target locations of siRNAs. *, siRNAs used for cell assays. b, 
Western blot analysis (24 hr post-transfection). c, Densitometric analysis of the protein 
expression (mean ± SEM). *, significantly different from nonsense control siRNA-
transfected cells, p < 0.001. Cont, nonsense control siRNA; S, Src; F, Fyn; Y, Yes. d, 
Immunocytochemical staining of Src in human RMECs. Nuclei were counterstained with 
DAPI. Arrow indicates a cell which failed to undergo RNAi in a Src siRNA-transfected 
cell population. Bar, 40 µm. 
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To study SFKs in VEGF-mediated endothelial cell events, Src, Fyn, or Yes siRNA 
each was used at a concentration of 300 nM for transfection in single or triple 
knockdowns. Nonsense siRNA was used at 300 nM or 900 nM serving as controls in all 
experiments. We did not observe any significant differences in VEGF-mediated 
endothelial cell events between the two concentrations of nonsense control siRNA. 
 
Western blot analysis 
Following siRNA-transfection, human RMECs were immediately cultured in 12-well 
plates at equal quantities. At harvest time, about 80% confluence, cells were washed with 
PBS and lysed with boiling 2X Laemmli SDS sample buffer (Sigma). Proteins were 
resolved by 10% SDS-PAGE minigels (Bio-Rad) and transferred to 0.2 µm nitrocellulose 
membranes (Bio-Rad). After incubation in blocking buffer, TBS (Sigma) with 0.1% 
Tween-20 (Sigma) and 5% nonfat dry milk (Bio-Rad), for 30 min at room temperature, 
blots were incubated with the primary antibody overnight at 4°C and with the secondary 
antibody for 2 hr at room temperature. Following thorough washing, proteins were 
visualized with enhanced chemiluminescence (Amersham). Blots were routinely stripped 
and reprobed for other proteins to obtain loading controls. Every experiment was 
repeated at least three times independently. 
Antibodies specifically recognizing individual Src, Fyn, or Yes were purchased from 
Upstate (Waltham, MA) and Santa Cruz Biotechnology. The Erk1/2 antibody was 
purchased from Cell Signaling (Beverly, MA). The β-actin antibody was purchased from 
Sigma. HRP-conjugated anti-rabbit or anti-mouse antibodies (Promega) were used as 
secondary antibodies. 
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Digitized images of Western blots were quantified using Image J software (NIH). 
Raw densitometric values of proteins were normalized against those of internal controls 
(i.e. untargeted proteins) and then used for statistical analysis. 
 
Immunocytochemistry 
Human RMECs were cultured on coverslips for 24 hr post-transfection. Cells were 
then washed with PBS, fixed with 3% paraformaldehyde (Sigma) for 30 min, 
permeabilized in 0.1% Triton X-100 (Sigma) for 5 min, and blocked in 1% bovine serum 
albumin (Jackson Immunoresearch) for 10 min. Coverslips were incubated with the 
primary antibody at appropriate working dilutions for 30 min. FITC-conjugated goat anti-
rabbit IgG antibody (Jackson Immunoresearch) was used as a secondary antibody. Nuclei 
were counterstained with DAPI (Sigma). Samples were viewed with a Zeiss fluorescence 
Axiophot upright microscope (Carl Zeiss Microimaging, Thornwood, NY), and images 
were taken using a MicroMax CCD camera (Princeton Instruments, Trenton, NJ). 
 
Cell proliferation assay 
Cell growth was quantified with a colorimetric cell proliferation immunoassay 
recognizing BrdU incorporation (Roche Applied Science, Indianapolis, IN). Following 
siRNA-transfection, human RMECs were immediately seeded in 96-well plates at 4 x 103 
cells per well. Twenty-four hours later, after washing with SF medium, cells were treated 
for 45 hr with either SF medium containing 1% FBS or SF medium containing 1% FBS 
and 25 ng/ml recombinant human VEGF 165 (R&D Systems). Five repeats were made 
per treatment. Cells were then labeled with BrdU in situ for 3 hr at 37˚C. The amount of 
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BrdU incorporation was measured according to the manufacturer’s instructions. The 
experiment was repeated six times independently. 
 
Apoptosis assay 
The enrichment of cytoplasmic mono- and oligonucleosomes due to DNA 
fragmentation was determined with a photometric cell death immunoassay (Roche 
Applied Science). Following siRNA-transfection, human RMECs were immediately 
seeded in 48-well plates at 8 x 103 cells per well. Twenty-four hours later, after washing 
with SF medium, cells were treated for 24 hr with either growth medium, SF medium, or 
SF medium containing 50 ng/ml VEGF, duplicated for each treatment. Cytoplasmic 
fractions of the cells were extracted. The amount of DNA fragmentation was then 
determined according to the manufacturer’s instructions. The experiment was repeated 
six times independently. 
 
Cell migration assay 
Cell migration was quantified with a modified transwell method using fluorescence 
labeling, as previously described (110). Following siRNA-transfection, human RMECs 
were immediately seeded in 6-well plates at 16 x 104 cells per well. Twenty-four hours 
later, cells were labeled in situ with 2 µM calcein AM (Molecular Probes, Eugene, OR) in 
growth medium for 20 min at 37˚C. After washing, cells were trypsinized and suspended 
in SF medium. Cells were equally divided into 4 parts and added to 8 µm FALCON® 
HTS FluoroBlok™ inserts (Becton Dickinson) coated with 0.1% gelatin. VEGF (25 
ng/ml) in SF medium was used as a chemoattractant in the lower wells, while SF medium 
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was added to the control wells, duplicated for each treatment. The plates were incubated 
for 3 hr at 37˚C. Fluorescence of cells that had migrated through the inserts was measured 
via a Synergy™ HT multi-detection microplate reader (Bio-Tek, Winooski, VT) in the 
bottom-read mode using excitation and emission wavelengths of 485 nm and 530 nm, 
respectively, and a gain of 50. The kinetics of cell migration was monitored every half an 
hour. Human RMEC migration began almost immediately upon initiation of the 
experiment and reached a plateau after 2 hr. The fluorescence of cells migrating towards 
VEGF was recorded 1 hr after the beginning of the experiment. The experiment was 
repeated three times independently. 
 
Tube formation assay 
In vitro formation of tubular structures by human RMECs was studied on a growth  
factor-reduced Matrigel® matrix (Becton Dickinson) in 48-well plates. Matrigel-coated 
wells were prepared according to the manufacturer’s instructions for the thick-gel 
method. Following siRNA-transfection, human RMECs were immediately seeded in 6-
well plates at 10 x 104 cells per well. Twenty-four hours later, cells were trypsinized, and 
equally divided into 2 parts and suspended in either SF medium or SF medium containing 
25 ng/ml VEGF. Cells were then seeded onto the matrigel layers, duplicated for each 
treatment. After 16 hr of incubation, images of tubes were captured using a DMC 
digitizing camera (Polaroid) mounted on an IMT-2 inverted microscope (Olympus). 
Three fields per well were used for quantitative analysis. The digital images were 
analyzed using Image J software. Capillary-like structures of more than two cell lengths 
were evaluated and the mean tube length per area of the field was calculated. The  
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experiment was repeated four times independently.  
 
Data analysis 
Although all electroporation parameters were kept constant, the amounts of cells that 
survived the procedure varied between independent experiments. To avoid further stress, 
cells were not recounted 24 hr post-transfection. At the beginning of each experiment, 
RNAi effects contributed to the disparity of cell numbers between different siRNA-
transfected cells. Therefore, all results generated using transfected and VEGF-treated 
samples are presented in relation to the appropriate control sample within each 
independent experiment.  
All experimental data were subjected to the ANOVA statistical test using Stat View 
software (Abacus Concepts). A value of p < 0.05 was considered significant. 
 
4.4 Results 
 
siRNAs mediate specific gene-downregulation of Src, Fyn or Yes in human RMECs 
We first confirmed that human RMECs were susceptible to gene specific RNAi with  
a validated synthetic β-actin siRNA. The knockdown efficiency of β-actin can reach more 
than 97% 24 hr post-transfection (Figure 4.2). In order to select an siRNA that would 
efficiently knock down Src in human RMECs, we tested eight sequences correspondent 
to different regions of Src mRNA (Figure 4.1). Interestingly, the siRNA targeting 5΄ UTR 
induced the most pronounced Src specific protein reduction. Thus, this probe was used in 
the following experiments and designated as Src siRNA. Using the electroporation  
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a. 
 
 
b. 
Figure 4.2. Human RMECs are susceptible to synthetic β-actin siRNA-mediated specific 
gene silencing, which is a transient phenomenon. β-actin and nonsense control siRNAs 
were transfected at a concentration of 200 nM. a, Western blot analysis of β-actin 
expression. b, Densitometric analysis shows that β-actin expression was significantly 
reduced at 24 hr, 48 hr, 72 hr, 96 hr post-transfection (p < 0.001) and 120 hr post-
transfection (p < 0.05) compared to nonsense control siRNA-transfected cells. Cells 
transfected with Src siRNA (300 nM) showed no reduction of β-actin expression 24 hr 
post-transfection. Bars represent the mean ± SEM. *, p < 0.05. 
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any of the proteins tested.  
Thus, using RNAi, we selectively knocked down Src, Fyn and Yes to similar extents 
in human RMECs. These synthetic siRNA-transfected human RMECs maintained typical 
endothelial morphology and conferred clear phenotypic changes in VEGF-mediated cell 
events. 
  
Src, Fyn and Yes are all required for VEGF-mediated cell growth in human RMECs 
 
VEGF is a powerful endothelial specific mitogen (57,97). Upon VEGF stimulation, 
SFKs function upstream of PLC-γ, which eventually leads to the activation of Raf-MEK-
Erk pathway and induces cell proliferation (100,111,112). In nonsense control siRNA-
transfected human RMECs, 25 ng/ml VEGF induced a 2.2-fold increase in cell growth 
versus the control medium containing 1% FBS. The induction of proliferation was 
significantly inhibited by 32 - 53% in cells deficient in individual Src, Fyn, or Yes (p < 
0.05). In Src, Fyn and Yes triple knockdown cells, VEGF-induced cell growth was 
impaired by about 56% (p < 0.005) (Figure 4.3). The remaining SFK activities which 
were not completely abolished by RNAi may have contributed in part to the residual cell 
growth observed. These results showed that Src, Fyn and Yes were all required for 
VEGF-induced cell proliferation. Each kinase may possess unique functions in VEGF 
mitogenic signaling that cannot be fully compensated by the other two kinases.  
 
SFK interference does not affect the anti-apoptotic effect of VEGF in human RMECs 
 
To investigate the specific roles of Src, Fyn, or Yes in the VEGF-mediated cell 
survival pathway, we quantified cell death by determining the enrichment of cytoplasmic 
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Figure 4.3. Src, Fyn and Yes are all required for VEGF-mediated cell growth in human 
RMECs. Cell proliferation was quantified with the BrdU incorporation. The absorbance 
of the VEGF-treated sample was normalized to that of its control sample treated with 1% 
FBS. VEGF-induced cell proliferation was expressed as an increase of the amount of 
BrdU incorporation in the VEGF-treated sample compared to that of the 1% FBS-treated 
control sample (mean ± SEM). *, significantly different from nonsense control siRNA-
transfected cells, p < 0.05. 
mono- and oligonucleosomes due to DNA fragmentation, a late event of apoptosis. In 
nonsense control siRNA-transfected cells, serum starvation for 24 hr induced a 2.0-fold 
DNA fragmentation compared to the growth medium condition (Figure 4.4a). In cells 
subjected to SFK single downregulation by Src, Fyn or Yes siRNA, we did not observe 
any difference of apoptosis induction by serum deprivation compared to nonsense control 
siRNA-transfected cells (p > 0.05) (Figure 4.4a), despite their significantly impaired cell 
growth in response to VEGF. Nor did these cells show any significant disruption of the 
VEGF survival effect (p > 0.05) (Figure 4.4b). In addition, Src, Fyn and Yes triple 
knockdown cells showed no significant change of DNA fragmentation upon serum 
starvation or VEGF administration compared to nonsense control siRNA-transfected cells 
(p > 0.05) (Figures 4.4, a and b). Thus, at these levels of protein downregulation, Src, Fyn 
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a. 
Figure 4.4. SFK interference does not affect the anti-apoptotic effect of VEGF in human 
RMECs. a, After serum starvation, the amounts of DNA fragments in nonsense control 
siRNA or SFK siRNA-transfected cells were not significantly different (p > 0.05). The 
absorbance of the SF medium-treated sample was normalized to that of the growth 
medium-maintained control sample (mean ± SEM). The experiment was repeated three 
times independently. b, VEGF-mediated cell survival from serum starvation was not 
significantly different among nonsense control siRNA or SFK siRNA-transfected cells (p 
> 0.05). DNA fragmentation of the VEGF-treated sample was expressed as the fraction o
that of the SF medium-treated sample (mean ± SEM). The experiment was repeated six 
times independently.  
f 
b. 
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and Yes appeared not as important to VEGF survival signaling as to mitogenic signaling.  
 
 
Src, Fyn and Yes differentially contribute to the modulation of VEGF-mediated cell 
migration in human RMECs 
 
In addition to its role as a mitogenic and survival factor, VEGF also functions as a 
chemoattractant and induces endothelial cell migration (38). Interference of Src, Fyn or 
Yes expression with siRNAs showed differential influences on endothelial chemotaxis 
towards VEGF (Figure 4.5). There was no significant change of cell motility in Src 
siRNA-transfected cells compared to nonsense control siRNA-transfected cells. 
Interestingly, cell migration was significantly increased (p < 0.01) in human RMECs 
transfected with Fyn siRNA, while significantly decreased (p < 0.05) in cells transfected 
with Yes siRNA. Nevertheless, Src, Fyn and Yes triple knockdown cells showed 
Figure 4.5. Src, Fyn and Yes differentially contribute to the modulation of VEGF-
mediated cell migration in human RMECs. The fluorescence (arbitrary unit) from cells 
migrating towards VEGF was normalized to that of cells migrating towards SF medium. 
Results were expressed as an increase in VEGF-induced cell migration compared to the 
random cell migration occurring in SF medium (mean ± SEM). *, significantly different 
from nonsense control siRNA-transfected cells, p < 0.05. 
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significantly impaired cell migration (p < 0.05), which was consistent with a previous 
finding that blocking SFKs in general inhibited endothelial cell migration (47). Thus, 
these results revealed differential properties of SFKs in the modulation of VEGF-induced 
cell migration, i.e. inhibition by Fyn and facilitation by Yes. Due to the incomplete 
knockdown of protein expression, the role of Src in VEGF-mediated cell migration 
remains undetermined.  
 
Interfering with Fyn alone or with Src, Fyn and Yes simultaneously perturbs VEGF-
mediated tube formation in human RMECs 
 
The roles of Src, Fyn and Yes in VEGF-mediated cell differentiation were assessed 
with a tube formation assay on growth factor-reduced matrigel (Figure 4.6). Interfering 
Src or Yes expression failed to disrupt VEGF-induced tube formation. The lack of 
phenotype did not exclude their possible roles in this cellular event due to the incomplete 
depletion of targeted proteins. However, the reduction in Fyn resulted in a significant 
perturbation of VEGF-induced tube formation (p < 0.02). Therefore, untargeted Src and 
Yes did not fully compensate for the deficient function of Fyn in these cells. We also 
observed significant inhibition of VEGF-induced tube formation in Src, Fyn and Yes 
triple knockdown cells (p < 0.05), even though the protein reduction was less than that in 
single knockdowns. This finding was consistent with a previous study showing that 
nonspecific inhibition of SFKs suppressed VEGF-induced angiogenesis in the chick 
chorioallantoic membrane in vivo (46).  
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Figure 4.6. Interfering with Fyn alone or with Src, Fyn and Yes simultaneously perturbs 
VEGF-mediated tube formation in human RMECs. a, Quantitative analysis of VEGF-
induced tube formation in siRNA-transfected cells. The mean tube length (µm) of the 
VEGF-treated sample was normalized to that of the SF medium-treated control sample. 
Results were expressed as an increase in VEGF-induced tube formation compared to the 
spontaneous formation of tubes occurring in SF medium (mean ± SEM). *, significantly 
different from nonsense control siRNA-transfected cells, p < 0.05. b, Phase contrast 
micrographs of formation of tube-like structures in siRNA-transfected cells. 
4.5 Discussion 
SFK members (e.g. Src, Fyn and Yes) are generally believed to have overlapping 
functions, but there is emerging evidence that evolutionary pressures may have yielded 
unique functions of individual family members (46,51). Even though the involvement of 
SFKs in VEGF-mediated angiogenesis has been clearly demonstrated over the last 
decade, there has not been an attempt to discriminate the specific roles of individual 
members. Using RNAi, we have shown that, in addition to their functional redundancy, 
closely related SFK members Src, Fyn, and Yes each possess functional specificity in 
VEGF-mediated endothelial cell events. First, Src, Fyn and Yes each play unique roles in 
VEGF mitogenic signaling. Second, they differentially contribute to the modulation of 
VEGF-mediated cell migration. Third, Fyn plays a unique role in VEGF-induced tube 
formation. Nevertheless, human RMECs, deficient in all three SFKs showed significant 
disturbances in these VEGF-mediated cell events (i.e. proliferation, migration and tube 
formation). Notably, human RMECs deficient in Fyn showed increased cell migration 
and decreased tube formation. Tube formation, per se, is a complex process, involving 
multiple steps, such as cell adhesion, extracellular matrix extrusion, cell migration and 
differentiation (95). It is possible that the roles of SFKs in cellular events other than 
migration contribute to this discrepancy.  
The distinctive functions of Src, Fyn or Yes in VEGF signaling may be due in part to 
their differential localizations in intracellular compartments (113,114), and consequently 
distinct association with various upstream activators and downstream substrates. SFKs 
can be associated not only with plasma membrane, but also with endosomes, the rough 
endoplasmic reticulum, secretory vesicles and caveolae (114,115). Myristylation and 
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palmitylation of the N-terminal sequences of SFKs mediate their targeting to membranes. 
Unlike myristylation, palmitylation is a reversible process (116), which may account for 
the relocalization of SFKs (113). Notably, the cysteine residue in the likely consensus 
palmitylation sequence (myr-Gly-Cys-) is present in Fyn and Yes, but not in Src. 
Additionally, positively charged lysine or arginine residues in the N-terminus of SFKs 
can provide an electrostatic mechanism to enhance membrane binding. Src, Fyn and Yes 
differ from each other in these regions (113). Electrostatic charges can also be modulated, 
for example, by phosphorylation (117). Thus, subcellular targeting of SFKs requires 
multiple signals and is modifiable, which may confer to each a set of distinctive 
biological profiles. SFKs can be coupled to and/or activated by many other cellular 
receptors, such as receptors for platelet-derived growth factor or epidermal growth factor. 
It can be expected that individual SFKs possess distinctive functions under influence of 
these receptors as well.  
VEGF-induced endothelial cell survival was reported to be mediated by PI 3-
kinase/Akt (39,47) and SFKs (46,47). Our data showed that despite significant inhibition 
of cell proliferation, interference of Src, Fyn or Yes individually or together, failed to 
disrupt the VEGF anti-apoptotic effect as measured by DNA fragmentation. Apoptosis is 
an active process, which can be detected by various morphological and biochemical 
criteria (118). Apoptotic cell surface change is an early event (119) and its occurrence 
precedes DNA fragmentation (120). A previous report showed that PP2, a selective SFK 
inhibitor, significantly increased annexin V labeling, a hallmark of apoptotic cell surface 
change, in serum-starved human umbilical-vein endothelial cells under VEGF protection. 
However, it did not impair VEGF protection from late apoptotic events, such as cell 
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detachment and FAK cleavage, as did a PI 3-kinase inhibitor (47). Consistent with this 
work, our data indicates that SFKs may not participate in late apoptotic events in 
endothelial cells, although they may influence early apoptotic features (47). 
Downregulation of Src, Fyn or Yes individually in human RMECs resulted in 
differential effects on VEGF-induced cell migration. This suggests that SFKs play 
important roles in the modulation of the VEGF migration signal. Particularly, VEGF-
induced cell migration was significantly increased in cells deficient in Fyn, which 
indicated an inhibitory effect of Fyn. It is known that VEGFR-1 activation alone fails to 
induce endothelial cell migration (38,40,121). However, VEGFR-1 activation is 
sufficient for the migration of monocytes, which naturally express the receptor (122,123). 
In addition, despite intact VEGFR-2 function, blocking VEGFR-1 alone can abolish 
VEGF-induced cell migration, which indicates an essential role for VEGFR-1 in cell 
motility (124). Gille and colleagues showed that the intracellular juxtamembrane region 
of VEGFR-1, which contained a stretch of three serines, constitutively functioned as a 
specific repressor of VEGFR-1-mediated VEGF-dependent migration in endothelial cells. 
Replacement of the juxtamembrane region of VEGFR-1 by that of VEGFR-2 gave 
VEGFR-1 the competence to induce endothelial cell migration (125). Thus, it has been 
suggested that there may be an inhibitory pathway in VEGFR-1-mediated migration in 
endothelial cells, which functions via the intracellular juxtamembrane region. This 
inhibitory regulation is likely void in monocytes, due to the different composition of the 
molecular machinery. Fyn has been shown to be associated preferentially with VEGFR-1 
(126), and it is phosphorylated upon VEGF stimulation in porcine aortic endothelial cells 
expressing VEGFR-1, but not in cells expressing VEGFR-2 (38). Combining these facts 
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with our observation, we propose that Fyn, as a membrane attached protein tyrosine 
kinase, may be involved in the inhibitory pathway of VEGFR-1-mediated migration in 
endothelial cells. In addition, silencing Yes resulted in impaired human RMEC migration, 
which indicates that Yes may function as a positive regulator. This regulation may be 
through VEGFR-2 or VEGFR-1 at sites other than the intracellular juxtamembrane 
region. Further work is required to determine the underlying mechanism. 
VEGF initiates and promotes pathological angiogenesis and vascular permeability in 
the retina (2,53,54). SFKs are key components of VEGF signal cascades. Family 
members Src, Fyn and Yes possess differential roles in the regulation of VEGF-mediated 
endothelial cell events, such as proliferation, migration, tube formation and vascular 
permeability. We show that human RMECs, the same cells that undergo dysregulated 
growth and differentiation in retinopathies, are susceptible to specific-gene silencing by 
RNAi. Together, these results raise the possibility that SFK member(s) may be 
selectively targeted, for example by RNAi, for intervention in VEGF-mediated 
pathological retinal angiogenesis and vascular leakage.   
To date, there has been no systematic efficiency study of siRNAs targeting various 
regions of mRNA. The 5΄ or 3΄ UTR or regions near the start codon are generally avoided 
due to abundant regulatory protein binding sites in these regions (104). However, siRNAs 
targeting the 3΄ UTR or a nearby vicinity were shown recently to effectively silence 
genes in mammalian cells (105). Here, we have shown that an siRNA duplex targeting 
the 5΄ UTR of Src mRNA successfully induced RNA interference, and it appeared to be 
more efficient than other tested siRNAs targeting the open reading frame. Using siRNAs 
targeting the 5΄ or 3΄ UTR to induce RNAi can be advantageous. For example, a plasmid 
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coding for a target gene or mutants can be introduced without interference, facilitating 
phenotypic verification or rescue.  
While searching for an siRNA which could efficiently knock down Src expression, 
we noticed that SFKs appeared to be less sensitive to synthetic siRNA-mediated RNAi 
(maximum knockdown of 60-70%) than β-actin (maximum knockdown of 97%) in 
human RMECs. We targeted eight sites of Src mRNA using siRNAs, all of which caused 
some measurable knockdown, and spanning nearly the entire mRNA. However, none of 
them exerted knockdown effects as profound as that of β-actin siRNA in human RMECs, 
nor did the previously validated Fyn and Yes siRNAs. Various factors may contribute to 
this phenomenon, such as cell type, intrinsic protein profiles (e.g. protein abundance and 
turnover rate) and accessibility of mRNA (127).  
Use of vector-based RNAi may achieve better silencing effects and longevity than the 
synthetic siRNA duplex. However, synthetic siRNAs are less likely to trigger interferon 
(IFN)-mediated activation of the Jak-Stat pathway and global upregulation of IFN-
stimulated genes (128,129), which would confound results. Nevertheless, while our study 
showed no evidence of general repression of protein synthesis in cells transfected with 
various siRNAs compared to wild type cells, broad effects of synthetic siRNAs must be 
considered and caution is warranted in interpreting findings. 
In the current work, we demonstrated the use of RNAi to study the biological 
functions of individual members of a gene family. While incomplete depletion of protein 
expression may have hampered the depth of our investigation, valuable phenotypic data 
were derived. We believe that RNAi may be used to interfere specifically in pathogenesis 
involving multiple, high homology member(s) of a gene family, potentially reducing 
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therapeutic complications due to nonspecific targeting.       
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5.1 Abstract 
VEGF-mediated retinal neovascularization involves both VEGF expression and 
signaling. Here we showed that in vitro SFKs were essential for hypoxia-induced VEGF 
expression in glial Müller cells and VEGF signaling in RMECs. However, neither 
process required phosphorylation of the SFK activation loop Tyr416. In vivo, in a rat 
model of OIR, we found a significant increase of retinal SFK Tyr416 phosphorylation, 
which was specifically associated with pathological angiogenesis. The OIR retinas also 
expressed significantly higher levels of VEGF than the healthy controls. Using 
immunohistochemistry and confocal microscopy, we identified Müller cells as the source 
of the elevated phospho-SFK Tyr416 signal. Intravitreous injection of a selective SFK 
inhibitor (PP2) significantly reduced retinopathy in the OIR model, indicating that SFKs 
acted as key regulators in abnormal retinal angiogenesis. Together, these data suggest that 
SFK activation via a Tyr416-dependent mechanism may be an important factor in the 
pathogenesis of retinal neovascularization. 
 
5.2 Introduction 
Retinal neovascularization is the leading cause of severe vision loss and irreversible 
blindness in developed countries, affecting people of all ages (1). It is the characteristic 
pathological event of diverse retinal diseases, such as ROP, retinal vein occlusion, 
diabetic retinopathy and sickle cell retinopathy. For the pathogenesis of these angiogenic 
conditions, retinal ischemia and hypoxia have been identified as a major driving force, 
and hypoxia-inducible VEGF as a crucial stimulator and regulator (2,5,130). In the 
vertebrate retina, Müller cells are the most abundant glial cells playing active roles in the 
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maintenance of retinal extracellular homeostasis and the metabolic support of neurons 
(87). They are the major VEGF secreting cell type in the retina during ischemia-induced 
neovascularization (11,89). VEGF is a potent vascular endothelial cell mitogen (60). Its 
high affinity tyrosine kinase receptors, VEGFR-1 (flt-1) and VEGFR-2 (KDR/flk-1), are 
expressed predominantly in endothelial cells (60). Biologically relevant VEGF-mediated 
endothelial cell events, such as proliferation, chemotaxis, survival and vascular 
permeability, are mainly regulated through VEGFR-2 (19,38-40). In the eye, RMECs 
undergo dysregulated proliferation and differentiation in proliferative retinopathies (2). 
As membrane-attached nonreceptor protein tyrosine kinases, broadly expressed SFKs 
link a variety of extracellular cues to intracellular signal pathways (43). Family members 
Src, Fyn and Yes are often coexpressed, e.g. in vascular endothelial cells (43-45). Recent 
studies revealed that SFKs were involved in both hypoxia-induced VEGF expression in 
cancer cells (18) and VEGF signaling in endothelial cells (46-48). However, their roles in 
the pathogenesis of VEGF-mediated retinal neovascularization are completely unknown. 
SFKs are 52- to 62-kDa proteins consisting of six distinct functional domains: a SH4 
domain involved in locating SFKs to cellular membranes, a unique domain, SH3 and 
SH2 protein-binding domains, a catalytic domain, and a negative regulatory carboxyl 
terminal tail (43). SFKs have two most important regulatory phosphorylation sites, 
Tyr527 in the negative regulatory tail and Tyr416 in the activation loop of the catalytic 
domain. Inactive SFKs are present in a restrained form via the intramolecular interaction 
of the SH2 domain with phospho-Tyr527 (pY527) and adjacent residues, which is critical 
for suppressing the kinase activity. The SH3 domain further stabilizes the inactive state 
by forming intramolecular interactions with amino acids within and adjacent to the 
 67
catalytic domain (43). When the intramolecular interactions are disrupted, dissociated 
pY527 may allow dephosphorylation. Tyr416 then undergoes autophosphorylation, 
which permits and stabilizes the active conformation, and promotes the intrinsic kinase 
activity (43,131). Boerner and colleagues showed that despite being present in the 
pY527-SH2 complex, Src with phospho-Tyr416 (pY416) retained 20% of the catalytic 
activity and could readily phosphorylate substrates (50). Autophosphorylation of Src at 
Tyr416 was shown to be directly correlated with its catalytic activity (50). In vivo, wild 
type SFKs are strictly regulated and mainly present in the restrained state (131). By 
coupling to signal molecules and phosphorylating substrates, SFKs participate in various 
cell signaling pathways (43).  
ROP is a major cause of blindness in infants. The pathogenesis of the disease follows 
a two-phase course: initial disruption of retinal vascularization and subsequent abnormal 
vasoproliferation (132). We have developed a rat model of OIR, which mimics the 
pathophysiological course of human ROP and produces retinopathy representative of the 
human disease counterpart (71,72).  
In this study, we investigated the roles of SFKs in VEGF-mediated retinal angiogenic 
events both in vitro in primary retinal cell cultures and in vivo in the rat model of OIR. In 
vitro, regulation of SFK activity via Tyr416 phosphorylation is not required for both 
VEGF expression under hypoxia in Müller cells and VEGF signaling in RMECs. In vivo, 
SFKs were highly phosphorylated at the activation loop Tyr416 in retinas with 
pathological retinal angiogenesis, but not in those with only physiological intraretinal 
vascularization. 
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5.3 Materials and Methods 
 
Materials 
Recombinant human VEGF 165 was purchased from R&D Systems. A selective SFK 
inhibitor, PP2, and its negative control, PP3, were purchased from Calbiochem (San 
Diego, CA). Antibodies recognizing SFKs in general, or individual Src, Fyn or Yes, or 
VEGFR-2 were purchased from Upstate and Santa Cruz Biotechnology. Antibodies 
recognizing SFK pY416 and phospho-Erk1/2 were purchased from Cell Signaling. 
Antibodies recognizing SFK pY527 and phospho-FAK Tyr861 (FAK pY861) were 
purchased from Biosource (Camarillo, CA). Antibodies recognizing vimentin and GFAP 
were purchased from DAKO. FITC-conjugated goat anti-mouse IgG antibody and RRX-
conjugated goat anti-rabbit IgG antibody were purchased from Jackson Immunoresearch 
Laboratories. HRP-conjugated anti-rabbit and anti-mouse antibodies were purchased 
from Promega. Unless otherwise specified, all other reagents were purchased from 
Sigma. 
 
Cell culture 
Primary cultures of bovine RMECs (VEC Technologies, Rensselaer, NY) from the 
6th to the 10th passage and human RMECs (Cell Systems) from the 5th to the 6th 
passage were used for in vitro studies. Bovine RMECs were routinely cultured in tissue 
flasks coated with a 50:50 solution of 100 µg/ml fibronectin-100 µg/ml hyaluronic acid 
in calcium- and magnesium-free PBS (Gibco). Cells were incubated in MCDB-131 
complete medium [MCDB-131, 10% FBS, 10 ng/ml epidermal growth factor, 1 µg/ml 
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hydrocortisone, 100 mg/500 ml Endo Gro (VEC Technologies), 45 mg/500 ml heparin, 
and 1X antibiotic-antimycotic solution]. Human RMECs were routinely cultured in tissue 
flasks coated with 0.1% gelatin in PBS and supplied with EGM (Cambrex) supplemented 
with 10% FBS. Both cell types were cultured in the standard cell culture atmosphere of 
5% CO2 and 95% air in a humidified incubator. When experimental conditions required a 
serum free medium, MCDB-131 medium containing 1X antibiotic-antimycotic solution 
was used.  
Primary retinal Müller cells were isolated from postnatal day 8 Long-Evans rat pups 
as previously described (90). The Müller cell identity was confirmed by positive staining 
for vimentin and negative staining for GFAP. Cells were cultured with DMEM (Gibco) 
supplemented with 10% FBS (Hyclone) and 1X antibiotic-antimycotic solution. Cells 
were routinely cultured in the standard cell culture atmosphere (20.9% oxygen; 
designated as “normoxic condition”). Passages from 3 to 5 were used for in vitro 
experiments. 
 
Western blot analysis 
Cells were washed with cold PBS and lysed with cold Buffer I (50 mM Tris-HCl, 150 
mM NaCl, 1% NP-40, 0.25% sodium deoxycholate, PH 7.4) containing protease and 
phosphatase inhibitors (1 mM EDTA, 1 mM PMSF, 1 µg/ml aprotinin, 1 µg/ml 
leupeptin, 1 µg/ml pepstatin A, 1 mM Na3VO4, 1 mM NaF). Retinal tissues were lysed by 
sonication at 4ºC in Buffer II (50 mM Tris-HCl, 150 mM NaCl, PH 7.4) containing 
protease and phosphatase inhibitors as above. After centrifugation, the supernatants were 
collected for protein quantification using a BCA protein assay (Pierce).  
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Equal amounts of protein samples were resolved by 10% SDS-PAGE minigels (Bio-
Rad). Proteins were then transferred to 0.2 µm nitrocellulose membranes (Bio-Rad). 
After incubation in the blocking buffer, TBS with 0.1% Tween-20 and 5% nonfat dry 
milk (Bio-Rad), for 30 min at room temperature, membranes were rinsed with TBS and 
incubated with the primary antibody in the blocking buffer overnight at 4°C. Then, 
membranes were washed with TBS and incubated with HRP-conjugated anti-rabbit or 
anti-mouse secondary antibody for 2 hr at room temperature. After thorough washing, the 
proteins were visualized by enhanced chemiluminescence (Amersham).  
Digitized images of Western blots were quantified using Image J software (NIH). 
Raw densitometric values were normalized against internal controls (i.e. β-actin) and then 
used for statistical analysis. 
 
Immunoprecipitation 
Cell lysates were centrifuged at 12,000 g for 15 min at 4°C. The supernatants were 
pre-cleared with protein A or G agarose bead slurry (50%; Pierce). Cell extracts, 1 mg 
per sample, were then incubated with the primary antibody for 2 hr at 4°C with gentle 
rocking. Immunocomplexes were captured by adding 100 µl protein A or G agarose and 
gently rocking for 30 min. Beads were then collected by pulse centrifugation (i.e. 10 sec 
at 10,000 g) and washed with cold Buffer I once and with cold PBS twice. Samples were 
boiled for 5 min in 2X Laemmli’s sample buffer and resolved with 10% SDS-PAGE gels.  
 
Interference of SFK expression with siRNAs 
Src siRNA, corresponding to the human Src cDNA sequence  
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AAGCAACTTGCCCAGCTATGA, and Fyn siRNA, corresponding to human Fyn 
cDNA sequence AAAGATGCTGAGCGACAGCTA (109), were chemically synthesized 
with symmetric 3΄ dTdT overhangs by Qiagen. Validated human Yes siRNA, β-actin 
siRNA and nonsense control siRNA were purchased from Ambion. 
siRNAs (300 nM) were transfected into 5 x 105 human RMECs by electroporation 
using a human lung microvascular endothelial cell Nucleofector™ kit (Amaxa) and a 
Nuclefector™ device (Amaxa) according to the manufacturer’s instructions. Immediately 
after electroporation, cells were resuspended in pre-warmed EGM with 10% FBS in the 
absence of antibiotics. Equal amounts of cells (approximately 80% confluence) were 
cultured in 12-well plates. Cells began to attach to culture vessels within 1hr after 
electroporation and, 24 hr later, about 80% of the seeded cells were viable. Cells were 
then washed with serum free medium, treated with 25 ng/ml VEGF, and lysed for 
Western blot analysis. 
We have characterized the use of these siRNAs in human RMECs and documented in 
detail elsewhere (Werdich XQ, Penn JS: Differentiation of the roles of Src, Fyn and Yes 
kinases in VEGF-mediated endothelial cell events by RNA interference. Manuscript 
submitted). Transfection of Src siRNA (300 nM) alone in human RMECs induced 66% 
specific downregulation of Src expression, 65% downregulation of Fyn expression by 
Fyn siRNA (300 nM), and 60% downregulation of Yes expression by Yes siRNA (300 
nM) 24 hr post-transfection. Simultaneous transfection of Src, Fyn and Yes siRNAs 
significantly reduced protein expression of Src, Fyn and Yes by 40 - 45% 24 hr post-
transfection. Nonsense control siRNA was used at 300 nM or 900 nM. Transfection of 
siRNAs at concentrations up to 1 µM showed no toxicity in human RMECs.  
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Hypoxia exposure of Müller cells 
Equal amounts of Müller cells were seeded in 6 cm-Petri dishes and maintained under 
normoxic conditions. When the cultures reached approximately 80% confluence, cells 
were washed and each dish supplied with 4 ml of fresh growth medium. In some 
experiments, PP2 was added at concentrations ranging from 1 µM to 20 µM. Cells were 
subjected to various hypoxic conditions or normoxia for 24 hr. Anoxic conditions (about 
0% oxygen) with a CO2-enriched environment were generated with BBL™ GasPak 
Pouch™ system (Becton Dickinson). Normoxic and other hypoxic conditions with 
oxygen concentrations ranging from 20.9% to 2.5% were generated by using an Isotemp 
laboratory CO2 incubator with O2 control (Kendro Laboratory). Temperature, humidity 
and CO2 concentration were controlled and maintained at all times. The culture media 
and cell lysates were collected for VEGF and protein quantification, respectively. The 
anoxic condition (about 0% oxygen) was identified as the optimal hypoxic condition for 
induction of VEGF expression in the primary rat Müller cell culture. 
 
Quantification of VEGF concentration 
VEGF concentrations (pg/ml) of Müller cell culture media or retinal lysates were 
determined using a colorimetric VEGF ELISA assay kit (R&D Systems) according to the 
manufacturer’s instructions. The VEGF concentrations (pg/ml) were then normalized to 
the total protein concentrations (mg/ml) of Müller cell lysates or retinal lysates, as 
determined by BCA.  
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A rat model of OIR and intravitreous injection 
For in vivo study, we used a well established rat model of OIR (71,72). Briefly, 
within 4 hr after birth, normalized litters of 16 Sprague-Dawley rat pups were placed with 
nursing dams in Isolette® infant incubators (Hill-Rom Services, Batesville, IN) with 
controlled oxygen environments. The animals were exposed to alternating periods of 
hyperoxia (50% oxygen) and hypoxia (10% oxygen) every 24 hr for 14 days, and then 
moved to room air. In rat pups, this treatment consistently produced retinopathy 
representative of human ROP post oxygen exposure (71). In other experiments, animals 
were exposed to a less extreme variable oxygen regimen with oxygen concentrations of 
40 and 15%. Unlike the 50/10% treatment, the incidence of retinopathy in these rats was 
rare (about 4.8%), and the severity was less than 1 clock hour (72). Therefore, the 
50/10% treatment is designated as the OIR model in this manuscript. Age-matched 
control rats were raised simultaneously in room air.  
Some animals were sacrificed at various post exposure days and their retinas were 
harvested for protein analysis or immunohistochemical staining. Others were subjected to 
intravitreous injection upon removal to room air. PP2 was used at a final concentration of 
10 µM in 0.1% DMSO, and vehicle DMSO was used at a final concentration of 0.1%. 
Before injection, animals were sedated by methoxyflurane (Pitman-Moore, Mundelein, 
IL) inhalation. Proparacaine hydrochloride 0.5% (Allergan, Irvine, CA) was topically 
applied to the cornea. Intravitreous injection of 2.5 µl PP2 (left eyes) or vehicle (right 
eyes) were administered with a 30-gauge syringe (Hamilton, Reno, NV) according to a 
procedure described by Shafiee et al (133). Following injection, neomycin/polymyxin 
B/gramicidin ophthalmic drops (Alcon, Fort Worth, TX) were topically applied. After 6 
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days in room air (postnatal day 20), animals were sacrificed and retinas were dissected 
for assessment of retinal neovascularization. Use and treatment of animals conformed to 
the Declaration of Helsinki principles. 
 
Immunohistochemistry 
Deparaffinized 5 µm-thick transverse sections of retinal tissue were antigen-retrieved 
with DAKO® target retrieval solution (DAKO) according to the manufacturer’s 
instructions. After blocking in SuperBlock® blocking buffer (Pierce), the sections were 
incubated with the primary antibody in SuperBlock® blocking buffer at 4°C for 
overnight and then with the FITC- or RRX-conjugated secondary antibody at room 
temperature for 2 hr. The retinal sections which were incubated in SuperBlock® blocking 
buffer without the primary antibody served as the negative control. After thorough 
washing, sections were coverslipped using a ProLong® antifade kit (Molecular Probes). 
Slides were observed and images were taken with a Zeiss LSM510 confocal microscope 
(Carl Zeiss Microimaging). 
 
Assessment of retinal neovascularization 
Retinal vasculature was stained using a histochemical method for detecting ADPase 
activity, according to a procedure previously described (134) adapted for our purpose 
(74). This method stains retinal vascular endothelia and their stem cells in rats of this age 
(135). The stained retinas were whole-mounted onto slides.  
The severity of retinal pathological neovascular development was semi-quantified by 
the clock-hour method (72,136). Briefly, each retinal surface was divided into twelve 
 75
parts (clock hours). Three masked investigators independently evaluated the number of 
clock hours containing abnormal blood vessel growth. Their assessments were averaged 
for each retina. The data was expressed in values varying from 0 (no pathology) to 12 
(involvement of entire retinal circumference). Counting the number of clock hours 
occupied by retinal neovascularization is an established unit of clinical assessment of 
human ROP. Retinas of age-matched room air rats showed no pathology. 
 
Data analysis 
Data were analyzed with Stat View software (Abacus Concepts). The ANOVA 
statistical test was used to analyze parametric data such as VEGF concentration and 
normalized densitometric values. The non-parametric data for retinal neovascularization 
obtained by the clock-hour method were analyzed with the Mann-Whitney test. For each 
test, p < 0.05 was considered significant.  
 
5.4 Results 
 
In vitro, regulation of SFK activity via Tyr416 is not required for SFK-mediated VEGF 
signaling in RMECs 
 
In both bovine and human RMECs cultured in either growth medium (data not 
shown) or serum free medium (Figure 5.1), we detected a constant level of SFK pY416. 
These wild type SFKs could actually phosphorylate substrates as measured in vitro using 
a kinase activity assay. VEGF stimulation did not increase the SFK pY416 signal in 
either cell type in both time course and dose response studies (Figure 5.1, a and b), nor 
was the in vitro catalytic activity changed (data not shown). Furthermore, the pY416  
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a. Bovine RMECs
 
 
 
 
b. Human RMECs c. Bovine RMECs  
d. Bovine RMECs 
Figure 5.1. In vitro, VEGF signaling in RMECs does not increase SFK Tyr416 
phosphorylation. Cells were serum-starved overnight. Unless specifically noted, VEGF 
was used at 25 ng/ml for 10 min. Each experiment was independently repeated at least 
three times. a, The time course and dose response studies in bovine RMECs. b, A time 
course study in human RMECs. c, A time course study of individual SFK members Src 
and Fyn in bovine RMECs. The protein expression level of Yes was lower than that of 
Src and Fyn, data not shown. d, Representative blots of experiments under modified 
conditions. Cells were cultured on plates coated with various concentrations of 
fibronectin (FN). 
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signal of individual Src, Fyn or Yes did not change (Figure 5.1c). Tyr861 of FAK is a 
major phosphorylation substrate of SFKs (137). Consistently, FAK pY861 showed no 
increase upon VEGF stimulation (Figure 5.1b). However, VEGF stimulation did 
significantly activate SFKs’ downstream signal molecules Erk1/2 (100,111,112) (Figure 
5.1, b and d). We considered the possibility that the culture conditions were not optimal 
for SFK quiescence, and that the pre-existing background signal of SFK pY416 may have 
masked a significant response of SFKs to VEGF stimulation. To address this, we 
conducted experiments with modified culture and stimulation conditions. These included 
a broad range of VEGF stimulation times (30 sec to 24 hr), different phosphatase 
inhibitors (such as pervanadate), and different starvation or surface coating conditions, 
etc. The results of these experiments were all consistent: VEGF stimulation did not 
significantly enhance phosphorylation of SFKs at the activation loop Tyr416, nor was the 
resting state of SFK pY416 (Figure 5.1d) and the kinase activity (data not shown) ever 
completely quiescent.  
Nevertheless, pretreatment with PP2, a selective SFK inhibitor, at various 
concentrations significantly blocked VEGF-induced phosphorylation of Erk1/2 in both 
bovine and human RMECs in a dose dependent manner (Figure 5.2a). PP2 binds to the 
adenosine triphosphate (ATP) pocket of SFKs, and is non-competitive against ATP for 
the inhibition of SFKs (138). The negative control PP3 exerted no impact on Erk1/2 
activation by VEGF (Figure 5.2a). 
Using the gene specific RNAi technique, we have efficiently knocked down Src, Fyn 
and Yes individually or simultaneously in human RMECs (Werdich XQ, Penn JS: 
Differentiation of the roles of Src, Fyn and Yes kinases in VEGF-mediated endothelial  
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a. Bovine RMECs Human RMECs 
 
 
 
 
 
c. 
Human RMECs b. 
Figure 5.2. In vitro, VEGF signaling in RMECs requires SFK activity. Serum-starved 
cells were treated with 25 ng/ml VEGF for 10 min. a, Inhibition of VEGF-induced E
activation by PP2, but not PP3. Unless specifically noted, cells were pre-incubate
10µM PP2 or PP3 for 2 hours. The experiment was independently repeated four tim
Inhibition of VEGF-induced Erk1/2 activation by specific downregulation of Src u
RNAi. c, Quantitative analysis of the effects of specific downregulation of Src, Fyn, o
Yes by RNAi on VEGF-induced Erk1/2 activation. The experiment was independently 
repeated three times. *, significantly different from VEGF-treated control cells whic
were transfected with the nonsense control siRNA, p < 0.05. Cont, nonsense control; S, 
Src; F, Fyn; Y, Yes; SFY, Src, Fyn and Yes. 
rk1/2 
d with 
es. b, 
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r 
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cell events by RNA interference. Manuscript submitted). VEGF-induced phosphorylation 
of Erk1/2 was significantly reduced in cells deficient in individual Src, Fyn, or Yes, and 
in cells deficient in all three SFKs (p < 0.05) (Figure 5.2, b and c). The remaining 
activities of SFKs which were not completely abolished by RNAi, may have contributed, 
at least in part, to the remaining Erk1/2 activation. Therefore, gene specific 
downregulation of SFKs by RNAi in human RMECs confirmed that SFKs were indeed 
required for VEGF signaling through the Raf-MEK-Erk pathway, and that Src, Fyn and 
Yes all contributed. 
In addition, we observed that VEGF stimulation induced rapid and substantial 
recruitment of SFKs to VEGFR-2 in both bovine and human RMECs. In human RMECs, 
two minutes after stimulation, the amount of VEGFR-2-associated SFKs was 
significantly increased by 1.8-fold, and 10 min post stimulation by 2.0-fold (Figure 5.3). 
Thus, SFKs were important molecular components of VEGF signal cascades. 
However, SFK activation via Tyr416 phosphorylation was not required for VEGF 
signaling in RMECs. 
b. 
a. 
Figure 5.3. In vitro, VEGF signaling in RMECs induces recruitment of SFKs to V
2. Serum-starved human RMECs were treated with 25 ng/ml VEGF. The experiment was 
independently repeated five times. a, Representative Western blots. b, Quantitative 
analysis of Western blots. *, p < 0.02. 
EGFR-
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In vitro, regulation of SFK activity via Tyr416 is not required for SFK-mediated VEGF 
expression under hypoxia in Müller Cells 
 
Müller cells are the predominant VEGF-secreting cell type in the retina during 
ischemia-induced hypoxia (11,89). In vitro, primary rat Müller cells secreted VEGF 
spontaneously even under normoxic culture conditions (i.e. 20.9% oxygen), which 
constituted a higher oxygen concentration than that normally found in the retina (8). In 
fresh growth medium, VEGF concentration was below the detection sensitivity of the 
ELISA assay. After 24 hr incubation, we found VEGF in the rat Müller cells culture 
medium at a level of 215.32 ± 56.47 pg/mg (VEGF concentration normalized to total 
protein concentration). Exposure of the cells to hypoxia (0% oxygen) induced 2.4-fold 
increase in VEGF production after 24 hr (p < 0.05) (Figure 5.4a). We did not observe any 
significant change in cell morphology under hypoxia.  
a. 
b. 
Figure 5.4. In vitro, regulation of SFK activity via Tyr416 is not required for SFK-
mediated VEGF expression under hypoxia in Müller cells. Nor, normoxia; Hypo, h
(0% oxygen). Each experiment was independently repeated at least three times. a, VEGF 
induction by hypoxia in Müller cells and its inhibition by PP2. *, significantly different 
from cells treated with hypoxia alone, p < 0.02. b, Wertern blot analysis (24 hr 
incubation). 
ypoxia 
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Using Western blot analysis, we consistently detected the pY416 signal of SFKs in 
Müller cells cultured under normoxic conditions (Figure 5.4b). Exposure of the cells to 
hypoxia did not increase the SFK pY416 signal (Figure 5.4b), despite a significantly 
increased VEGF production (Figure 5.4a). The time course study and exposure of cells to 
other hypoxic conditions (2.5 to 10% oxygen) revealed no change either (data not 
shown).  
In order to clarify the role of SFKs in the hypoxia-induced VEGF production 
pathway, we cultured Müller cells under hypoxic conditions (0% oxygen) in the presence 
of PP2. PP2 did, in fact, significantly reduce VEGF production in a dose dependent 
manner (Figure 5.4a). Control treatments with DMSO alone or with the negative control 
PP3 at the same concentration resulted in no change on VEGF production. 
Therefore, while SFKs were clearly required for VEGF production under hypoxia, 
regulation of SFK activity via a Tyr416-dependent mechanism was not.  
 
In vivo, significantly increased retinal SFK Tyr416 phosphorylation correlates with 
elevated retinal VEGF levels in a rat model of OIR  
 
The OIR model (50/10% oxygen treatment) consistently produced retinopathy in rat 
pups (Figure 5.5b). The retinal VEGF expression was significantly increased at all tested 
post-exposure ages compared to room air controls (p < 0.05) (Figure 5.6a). Upon removal 
to room air, oxygen-treated animals showed the highest retinal VEGF level with a 6.6-
fold increase compared to their room air controls. VEGF expression dropped later during 
the first day post-exposure and then gradually increased, before dropping again as 
measured on day 6 post-exposure. We hypothesize that the substantially elevated retinal 
VEGF expression at the end of the oxygen exposure resulted mainly from the oxygen 
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b. c. 
40/15% Oxygen
a. 
Room Air OIR 
Figure 5.5. Demonstration of the retinal vasculature. Rat retinas were harvested on day 6 
post oxygen exposure (postnatal day 20) and stained for ADPase activity. a, A retina of 
room air control animals. b, An OIR (50/10% oxygen treatment) retina. The insert shows 
the vascular pathology at a higher magnification. c, A retina from the 40/15% oxygen 
treatment group. 
treatment (30). The subsequent VEGF increase during the post-exposure period in room 
air was also due to ischemia-induce hypoxia in non-perfused retinal tissue (11).  
Using Western blot analysis, we found that phosphorylation of the SFK activation 
loop Tyr416 was significantly increased in OIR retinas compared to room air controls, 
when measured on various post-exposure days (Figure 5.6b). Upon removal of animals to 
room air, SFK pY416 was observed at the highest level which later gradually tailed off, a 
pattern which was consistent with the retinal VEGF profile. We did not see a decreased 
SFK pY527 signal in these retinas compared to the room air controls (Figure 5.6b). SFK 
protein levels showed no significant different between OIR retinas and room air controls 
(Figure 5.6b). Tyr861 of FAK, a substrate of SFKs, was highly phosphorylated in OIR 
retinas with a profile similar to that of SFK pY416 (Figure 5.6b). Retinal phospho-Erk1/2 
showed only a modest difference between oxygen-treated samples and room air controls. 
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a. 
 
 
 
 
 
b. 
c. 
Figure 5.6. In vivo, significantly increased retinal SFK Tyr416 phosphorylation 
correlates with elevated retinal VEGF levels in a rat model of OIR. Each experiment was 
independently repeated at least three times. a, The retinal VEGF profile in OIR rats (n = 
36) and room air controls (RA, n = 17). Retinal VEGF of OIR rats was significantly 
higher than that of controls on all tested ages, p < 0.05. b, The SFK profile in the OIR 
retinas. Retinas were harvested on post exposure day 0, 3 and 6. c, The SFK profile in the 
40/15% retinas. Retinas were harvested on post exposure day 0 (postnatal day 14). 
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In a previous study, we demonstrated that the higher amplitude of the fluctuating 
inspired oxygen resulted in higher incidence and severity of retinopathy in rat pups (72). 
An oxygen regimen cycling between 40 and 15% oxygen constituted the maximum 
oxygen variation without producing retinopathy in rat pups (Figure 5.5c). Nevertheless, 
immediately after oxygen exposure, these retinas showed an average avascular area 
which was 14% of the total retina area, while room air controls were fully vascularized. 
There was also a 2.7-fold increase in the retinal VEGF level compared to the room air 
control (72,139). Unlike OIR retinas, we did not observe any increase of the SFK pY416 
signal or phosphorylation of FAK Tyr861 in these retinas compared to room air controls 
(Figure 5.6c).  
Thus, significantly increased phosphorylation of the SFK activation loop Tyr416 was 
specifically seen in the OIR retina.  
 
Immunohistochemical staining pattern of the elevated SFK pY416 signal in the OIR 
retina is consistent with Müller cell localization 
 
To further investigate the cellular source of the elevated retinal SFK pY416 signal 
seen in Western blots, we performed an immunohistochemical analysis of retinal 
transverse sections using confocal microscopy. In the OIR retina harvested immediately 
after removing animals to room air, many cell somas located in the middle region of the 
inner nuclear layer (INL) displayed increased SFK pY416 staining, as compared to the 
age-matched room air control (Figure 5.7a). Longitudinally, they resided in the peripheral 
retina, approximately extending from the location of the retinal vascular frontier towards 
the retinal margin (data not shown). These immunoreactive cell bodies displayed an 
irregular shape with processes projecting from the main trunk, as shown in the insert of  
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a. 
b. 
Figure 5.7. In vivo, immunohistochemical analysis of the SFK pY416 signal in the r
Retinas were harvested on post exposure day 0 and 6. ONL, outer nuclear layer; INL, 
inner nuclear layer; IPL, inner plexiform layer; GCL, ganglion cell layer. Bar, 20 µm. a,
The staining pattern of the increased SFK pY416 signal in OIR retinas consistent with 
Müller cell localization (the white arrow). Adjacent slides were stained for vimentin. The 
black arrow with white edge denotes normal retinal blood vessels, which grew from the 
superfacial network towards the deep network. b, The staining pattern of SFK pY416 in 
the normal intraretinal vessels (the black arrow with white edge) and pathological 
preretinal vascular tufts (the white arrow). Adjacent slides were stained for GFAP. 
etina. 
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Figure 5.7a. The location and morphology of these cells identified them as Müller cells 
(140). The increased SFK pY416 signal in the INL trended to subside during the post 
exposure period, which was consistent with the Western blot profile of SFK pY416. 
Vimentin-staining revealed radially oriented processes of Müller cells spanning nearly 
the entire depth of the retina which supported our assumptions concerning the SFK 
pY416-positive cells. There was no significant difference in the vimentin-staining pattern 
among retinas derived from OIR rats and room air controls.  
We also observed that the normal intraretinal vascular beds, including both superficial 
and deep networks, were positively stained for SFK pY416 (Figure 5.7, a and b). The 
staining intensity was consistent among tissues harvested from OIR rats and from room 
air controls on various post-exposure days (Figure 5.7b). On day 6 post exposure, 
abnormal blood vessel growth was seen in OIR retinas but not in room air controls. Those 
vessels penetrated the inner limiting membrane (ILM), grew into the vitreous, and formed 
preretinal neovascular tufts. These tufts were mainly composed of hyperplastic 
endothelial cells (72), which were also positively stained by the SFK pY416 antibody 
(Figure 5.7b). There was no significant difference in the intensity of SFK pY416 staining 
in intraretinal blood vessels and preretinal neovascular tufts. GFAP staining showed 
astrocytes which were restricted to the nerve fiber layer (NFL) (Figure 5.7b, lower panel). 
During the development of the superficial retinal vascular network, astrocytes function as 
a guide for endothelial cell migration and are closely associated with blood vessels (93). 
However, in OIR retinas, they failed to accompany the proliferating endothelial cells into 
preretinal neovascular tufts.  
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Intravitreous injection of PP2 significantly reduced retinopathy in a rat model of OIR 
The importance of SFKs in retinal neovascularization is evidenced by our in vitro and 
in vivo findings. In vitro experiments identified 10 µM PP2 as an optimum concentration 
for inhibiting SFK-mediated VEGF induction by hypoxia in Müller cells and VEGF 
signaling in RMECs. In OIR rats, intravitreous injection of PP2 (10 µM) upon removing 
animals to room air significantly inhibited retinopathy by 33% compared to the vehicle 
control injection. The severity of retinopathy semi-quantified by the clock-hour method 
showed a median of 4 with a range of 2-7.5 for the PP2-injected eyes, and a median of 6 
with a range of 2-10 for the vehicle-injected eyes, p < 0.01 (Figure 5.8a). The size of the 
retinal area involving pathological neovascularization was also markedly reduced, as 
shown in Figure 5.8b.  
 
5.5 Discussion 
Our results clearly demonstrated that SFKs are involved in VEGF-mediated retinal 
neovascularization. In vitro, SFKs were required for both VEGF expression under 
hypoxia in Müller cells and VEGF signaling in RMECs. In vivo, in a rat model of OIR, 
the activation loop Tyr416 of SFKs was highly phosphorylated, which paralleled 
significantly increased retinal VEGF. Our immunohistochemical analysis revealed that 
the elevated SFK pY416 signal originated from Müller cells, which have previously been 
shown to constitute a predominant source of VEGF secretion during the pathogenesis of 
retinopathy (11,89). A significant inhibition of retinopathy by intravitreous injection of a 
selective SFK inhibitor, PP2, in the OIR rats confirmed that SFKs were key regulators of 
the abnormal retinal blood vessel growth. 
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a.  
 
 
 
b. 
PP2-Treated Vehicle-Treated 
Figure 5.8. In vivo, intravitreous injection of PP2 significantly reduces retinal 
neovascularization in a rat model of OIR. PP2, 10 µM; vehicle, 0.1% DMSO in sterile 
PBS. Animals, n = 17. a, Demonstration of the severity of retinopathy (clock hours) by 
box graph. The black dot denotes the mean; the line within the box denotes the median; 
the vertical bar denotes the range. The two treatments were significantly different from 
each other at p < 0.01. b, Demonstration of the severity of retinopathy with ADPase-
stained retinas. Arrows denote preretinal neovascularization. 
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In quiescent bovine and human RMEC cultures, we showed that VEGF stimulation 
could activate SFKs’ downstream signal molecules-Erk1/2 (100,111,112) without 
increasing SFK Tyr416 phosphorylation and their intrinsic catalytic activity under 
various experimental conditions. Consistently, our in vivo data showed that the SFK 
pY416 signal was equivalently detected in intraretinal vessels and preretinal vascular 
tufts in OIR and normal retinas, even though the VEGF level in OIR retinas was 
significantly higher than that in room air controls. Thus, Tyr416-dependent SFK 
activation is not required for SFK-mediated VEGF signaling in RMECs both in vitro and 
in vivo. 
In the retina, Müller cells are the main storage site for glycogen, principally obtaining 
ATP through glycolysis and consuming little oxygen (88). They are highly resistant to 
hypoxia and hypoglycemia which allows them to function normally in a perturbed 
environment, such as during ischemia. Our in vitro data showed that VEGF expression 
under hypoxia in Müller cells required SFK activity, which, however, was not correlated 
to an increase in Tyr416 phosphorylation. This finding was consistent with our in vivo 
data from rats treated with the 40/15% oxygen regimen. During the post exposure period, 
there was a continuous process of hypoxia-induced retinal VEGF expression and 
intraretinal vascularization. However, we did not observe any increase of the SFK pY416 
signal in these retinas compared to age-matched room air controls, in which the retinal 
vasculature has fully developed. Therefore, Tyr416-dependent SFK activation is not 
required for SFK-mediated VEGF expression under hypoxia in Müller cells both in vitro 
and in vivo. 
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It is generally believed that upon stimulation, the catalytic activity of cellular SFKs is 
increased via phosphorylation of Tyr416 (43). This would allow them to phosphorylate 
substrates and participate in various signaling events, as previously shown in hypoxic 
induction of VEGF in U87 glioma cells and kidney 293 cells (18), or in platelet-derived 
growth factor signaling in various cell types (109,141). Conversely, our data show that 
regulation of SFK activity via a Tyr416-dependent mechanism was not always required 
for SFK signaling. Specifically, we found that SFK-mediated VEGF expression under 
hypoxia in Müller cells and VEGF signaling in RMECs could occur without an increase 
of Tyr416 phosphorylation. In vivo, SFKs may exist in four possible forms dependent on 
the phosphorylation states of Tyr527 and Tyr416 (131). It has been shown that Src, which 
is unphosphorylated at Tyr416, has a basal kinase activity and can readily phosphorylate 
substrates (142). In addition, the phospho-Tyr416 form of Src, even being in the 
intramolecular SH2-pY527 complex, retains about 20% of its catalytic activity and can 
phosphorylate substrates (50). In quiescent Müller cells and RMECs, we consistently 
detected a SFK pY416 signal. This indicates that at least a fraction of cellular SFKs is 
phosphorylated at Tyr416. In fact, these wild type SFKs could actually phosphorylate 
substrates (e.g. enolase) in vitro. We believe that both the SFK basal kinase activity and 
the pY416-related regulatory activity may have contributed to the kinase activity. We 
propose that, in some circumstances, wild type SFKs retain a baseline kinase activity, 
which is physiologically relevant. This baseline kinase activity is sufficient for signal 
transduction through SFKs. Takahashi and Shibuya reported that SFKs were not activated 
by VEGF in sinusoidal endothelial cells using an in vitro kinase assay (143), while others 
demonstrated that SFKs were, indeed, required for VEGF signal pathways in human 
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umbilical vein endothelial cells using SFK inhibitors or a kinase-deleted Src mutant 
(47,48). Cary and colleagues showed that although Src kinase activity was necessary for 
integrin-signaling in fibroblasts, it did not need to be upregulated by phosphorylation of 
Tyr416 (142).  
However, under some pathological conditions, SFKs can indeed become highly 
activated via phosphorylation of Tyr416. In OIR retinas, we consistently observed a 
significantly increased SFK pY416 signal compared to the retinas from the 40/15% 
oxygen treatment group and the room air control group. We suspect that this Tyr416-
dependent SFK activation may be involved in the pathophysiological course of OIR. It is 
not yet clear why and how SFKs are activated at Tyr416. SFK activation in Müller cells 
can be a direct consequence of retinal ischemia and oxygen insult, or an indirect response 
to severely stressed neurons during and post oxygen exposure. Since SFKs were activated 
only in the retinas of the 50/10% treatment group, but not in those of the moderate 
40/15% treatment group, there may be a threshold for hypoxia and ischemia tolerance in 
the retinal tissue. Consequently, severe disturbances of the retinal physiological 
environment lead to SFK activation and retinopathy. 
Although there is no direct link between activated SFKs and excessive VEGF 
production by Müller cells in the OIR retina, several lines of evidence support this 
hypothesis. First, SFK activation in OIR retinas was correlated with drastically increased 
retinal VEGF levels post oxygen exposure. Second, SFKs were activated in the somas of 
Müller cells, where increased VEGF expression has been localized in the ischemic retina 
(11,89,93). Third, the distribution of cells with increased levels of SFK pY416 
approximated the peripheral avascular retinal region. More significantly, in U87 glioma 
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cells, overexpression of Src resulted in increased VEGF transcription under hypoxia. 
Transfection with v-Src constitutively increased the VEGF mRNA level even in the 
absence of hypoxia (18). In addition, activated SFKs in Müller cells may participate in 
other undefined pathophysiological events. For example, glial cells have been shown to 
influence the blood-brain barrier properties(144). However, it remains possible that SFK 
activation in the OIR retina is a consequence rather than a cause of pathological or 
physiological events.  
Significant increase of SFK expression and/or catalytic activity has been observed in 
a variety of tumors. This elevated SFK activity was shown to be correlated with the stage 
and metastatic potential of some neoplasia, which identified the activated SFKs as 
potential targets for intervention in turmorigenesis (145). Here, we report that 
significantly increased phosphorylation of the activation loop Tyr416 of SFKs was 
associated with the pathogenesis of retinopathy in a rat model of OIR, but not in the 
physiological intraretinal vascularization. The mechanism of SFK activation at Tyr416 
and its roles in the pathophysiological course warrant further characterization. Ultimately, 
this may lead to a discrimination of important molecular and cellular differences between 
physiological retinal vascular development and pathological retinal neovascularization. 
The detailed knowledge of SFK activation and subsequent abnormal cellular functions 
may facilitate rational design of therapeutic strategies which selectively target 
pathological events and minimize the unfavorable impact on physiological cellular 
functions.    
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CHAPTER VI 
 
CONCLUDING REMARKS 
 
Hypoxia inducible VEGF plays a major role in initiation and mediation of retinal 
neovascularization in various diseases such as ROP. We have developed a rat model of 
OIR which mimics the pathophysiological course of human ROP. Exposure of newborn 
rat pups to alternating periods of hyperoxia and hypoxia can interrupt the development of 
normal retinal vasculature and lead to tissue ischemia. Retinal glial Müller cells are the 
major VEGF secreting cell type during the pathophysiological course of OIR. 
Dysregulated retinal VEGF signaling disturbs the delicate balance of pro-angiogenic and 
anti-angiogenic factors. It results in abnormal RMEC proliferation and differentiation. 
SFKs are important molecular components of the VEGF expression pathway during 
hypoxia in Müller cells and of VEGF signal cascades in RMECs.  
Although SFKs have been indicated as candidate tyrosine kinases upstream of HIF-1 
in the hypoxia-induced gene expression pathway (14), the underlying molecular 
mechanism is largely unknown. Hypoxia exposure of primary rat Müller cell cultures 
may serve as a ready venue for studies of this signal pathway in vitro. The proteins 
associated with SFKs in this signal cascade may be identified using immunoprecipitation 
or the yeast two-hybrid system. The SFK substrates may be identified using the method 
of KESTREL (kinase substrate tracking and elucidation) (146). 
In vitro, we demonstrated that SFK members Src, Fyn and Yes have differential 
functions in regulation of VEGF-mediated endothelial cell proliferation, migration and 
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tube formation. Previously, Eliceiri and colleagues also showed that Src and Yes, but not 
Fyn were involved in VEGF-mediated vascular permeability (46). Together, these raise 
the possibility that SFK member(s) may be selectively targeted for inhibition of VEGF-
mediated pathological events. Our data strongly motivate further investigation of the 
molecular mechanism of each signal cascade involved. Future work can first focus on the 
clear-cut finding shown in Figure 4.5. The involvement of Fyn in the inhibitory pathway 
of VEGFR-1-mediated endothelial cell migration is hypothetical. Initial experiments 
should answer the question of whether or not there is a link between the two inhibitory 
pathways. Evidence may be found by studying the effects of Fyn downregulation on 
VEGFR-1-mediated cell migration using, for example, porcine aortic endothelial cell 
lines which stably express wild type or mutant VEGFR-1 (38,125). To reveal the 
underlying molecular mechanism, both binding activity and catalytic activity of Fyn 
should be considered, since one may participate in a signal event independent of the 
other. Mutational analysis is highly recommended, which will facilitate pinpointing the 
functional region(s), in turn providing valuable information about molecular mechanisms. 
Unlike VEGF induction by hypoxia in U87 glioma cells or PDGF signaling, VEGF 
induction by hypoxia in Müller cells and VEGF signaling in RMECs do not require 
activation of SFKs by phosphorylation of Tyr416, although SFKs are clearly required. 
Apparently, the baseline kinase activity of wild type SFKs in these cells can 
phosphorylate substrates sufficiently to propagate signals. Since the SFK pY416 signal is 
detected in quiescent wild type cells, at least some fraction of cellular SFKs is 
phosphorylated at Tyr416. Although there is considerable structural information available 
for the inactive “closed” conformation of SFKs, it remains unclear how they may 
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assemble into active signaling complexes with substrates and regulators. In addition, 
SFKs possess three distinct functions, the basal kinase activity of the kinase domain, the 
regulated kinase activity via phosphorylation of Tyr416, and SH2 and SH3 binding 
functions. Each of them may play functionally unique roles in SFK-mediated signal 
transduction pathways (142). In order to define the molecular mechanism of SFK-
mediated signal pathways, the following Src mutants will be of value: the kinase dead 
mutant (K295R), the unregulatable kinase mutant (Y416F), SH2 or SH3 domain mutants 
(T215W or D99N) (142).  
In vivo, our data showed that significant SFK activation via phosphorylation of 
Tyr416 was specifically involved in the pathogenesis of OIR, but not in physiological 
intraretinal vascularization. Many more questions need to be addressed, such as: how are 
SFKs activated in vivo in the OIR model? what other ischemic retinopathies involve SFK 
activation? what are the roles of activated SFKs in the pathogenesis of retinopathy? 
Overexpression of v-Src or the constitutively active Src mutant (Y527F) in primary 
Müller cell cultures would not only confirm the role of activated SFKs on VEGF 
transcription, but also provide useful information about other physiological events in 
Müller cells which may be altered during an increased SFK activity. Coculture analysis 
of Müller cells and retinal neurons, and retinal tissue culture analysis may provide 
valuable information about the impact of neurons on the cellular functions of Müller cells 
under hypoxia. 
Further characterization of the roles of SFKs in retinal neovascularization will 
facilitate rational design of therapeutic strategies targeting the SFK-mediated 
pathological events for inhibition. 
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